

# BMJ Open

## Diabetes and antenatal milk expressing (DAME): protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006571
Article Type:	Protocol
Date Submitted by the Author:	12-Sep-2014
Complete List of Authors:	Forster, Della; Royal Women's Hospital, Maternity; La Trobe University, Judith Lumley Centre Jacobs, Susan; Royal Women's Hospital, Neonatal Services Amir, Lisa; La Trobe University, Judith Lumley Centre Davis, Peter; Royal Women's Hospital, Neonatal Services Walker, Susan; University of Melbourne, Obstetrics and Gynaecology McEgan, Kerri; Mercy Hospital for Women, Opie, Gillian; Mercy Hospital for Women, Donath, Susan; Murdoch Childrens Research Institute, Clinical Epidemiology and Biostatistics Unit Moorhead, Anita; Royal Women's Hospital, Maternity; La Trobe University, Judith Lumley Centre Ford, Rachel; Royal Women's Hospital, Maternity McNamara, Catherine; Mercy Hospital for Women, Diabetes in pregnancy Aylward, Amanda; Royal Women's Hospital, Dietetics Gold, Lisa; Deakin University, Deakin Health Economics
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Paediatrics, Diabetes and endocrinology, Nutrition and metabolism
Keywords:	Diabetes in pregnancy < DIABETES & ENDOCRINOLOGY, NEONATOLOGY, Maternal medicine < OBSTETRICS, NUTRITION & DIETETICS

SCHOLARONE™  
Manuscripts

# Diabetes and antenatal milk expressing (DAME): protocol for a randomised controlled trial

Della A Forster<sup>1,2\*</sup>, Susan Jacobs<sup>2,3,4</sup>, Lisa H Amir<sup>1</sup>, Peter Davis<sup>2</sup>, Susan P. Walker<sup>4,5</sup>, Kerri McEgan<sup>5</sup>, Gillian Opie<sup>4,5</sup>, Susan M Donath<sup>6</sup>, Anita M. Moorhead<sup>1,2</sup>, Rachael Ford<sup>1,2</sup>, Catharine McNamara<sup>5</sup>, Amanda Aylward<sup>2</sup>, Lisa Gold<sup>7</sup>

## Author affiliations

<sup>1</sup>Judith Lumley Centre (formerly Mother & Child Health Research), La Trobe University, 215 Franklin Street, Melbourne, Victoria 3000, Australia

<sup>2</sup>Royal Women's Hospital, 20 Flemington Rd, Parkville, Victoria 3052, Australia

<sup>3</sup>Clinical Sciences, Murdoch Childrens Research Institute, PO Box 911, Parkville Victoria 3052, Australia

<sup>4</sup>Department of Obstetrics and Gynaecology, University of Melbourne, Victoria 3010, Australia

<sup>5</sup>Mercy Hospital for Women, 163 Studley Road, Heidelberg, Victoria 3084, Australia

<sup>6</sup>Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research Institute, PO Box 911, Parkville Victoria 3052, Australia

<sup>7</sup>Deakin Health Economics, Deakin University, Burwood, Victoria 3125, Australia

## \*Corresponding author:

Prof Della Forster  
Judith Lumley Centre  
La Trobe University  
Level 3  
215 Franklin St  
Melbourne VIC 3000  
AUSTRALIA

Word count, excluding title page and abstract: 5490

References: 52

Figures: 1

Tables 1

## ABSTRACT

### Introduction

Many maternity providers recommend that women with diabetes in pregnancy express and store breast milk in late pregnancy so breast milk is available after birth, given 1) infants of these women are at increased risk of hypoglycaemia in the first 24 hours of life; and 2) the delay in lactogenesis II compared to women without diabetes that increases their infant's risk of receiving infant formula.

The Diabetes and Antenatal Milk Expressing (DAME) trial will establish whether advising women with diabetes in pregnancy (pre-existing or gestational) to express breast milk from 36 weeks gestation increases the proportion of infants who require admission to special or neonatal intensive care units (SCN/NICU) compared with infants of women receiving standard care.

Secondary outcomes include birth gestation, breastfeeding outcomes and economic impact.

### Methods and analysis

Women will be recruited from 34 weeks gestation to a multi-centre, two arm, unblinded randomised controlled trial. The intervention commences at 36 weeks. Randomisation will be stratified by site, parity and diabetes type. Women allocated to the intervention will be taught expressing and encouraged to hand express twice daily for ten minutes and keep an expressing diary. The sample size of 658 (329 per group) will detect a 10% difference in the proportion of babies admitted to SCN/NICU (85% power, alpha 0.05). Data are collected at recruitment (structured questionnaire), after birth (abstracted from medical record blinded to group), and at 2 and 12 weeks postpartum (telephone interview). *Data analysis*: the intervention group will be

1  
2  
3 compared with the standard care group by intention to treat analysis, and the primary outcome  
4 compared using chi-square and odds ratios.  
5  
6  
7  
8  
9

### 10 **Ethics and dissemination**

11  
12 Research ethics approval will be obtained from participating sites. Results will be published in  
13 peer reviewed journals and presented to clinicians and policy makers.  
14  
15  
16  
17  
18  
19

20 **Trial Registration:** Australian Controlled Trials Register ACTRN12611000217909  
21  
22  
23

### 24 **Keywords**

25  
26 breast milk, breastmilk, maternal diabetes, gestational diabetes, breastfeeding, randomised  
27 controlled trial (RCT), antenatal expressing, hypoglycaemia, infant, newborn  
28  
29

### 30 **Strengths and limitations of this study**

31  
32 This will be the first study to provide rigorous evidence regarding the practice of antenatal  
33 expression of colostrum in late pregnancy for women with diabetes in pregnancy. It will explore  
34 the safety and efficacy for mother, fetus and infant.  
35  
36  
37  
38  
39  
40  
41  
42

## 43 **BACKGROUND**

44  
45  
46 Diabetes is the second highest contributor to loss of health in Australia.<sup>1</sup> Type 2 diabetes and  
47 gestational diabetes (GDM) are increasing globally.<sup>2</sup> GDM occurs on average in 7% of  
48 pregnancies (range 1 to 14% depending on the population characteristics and diagnostic tests  
49 used),<sup>2</sup> and is the strongest single population predictor of type 2 diabetes.<sup>3</sup> An additional 1% of  
50 females aged below 44 years have pre-existing diabetes (type 1 or 2),<sup>4</sup> with type 2 diabetes  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 increasing in women of childbearing age.<sup>5</sup> Since 2009, women found to have glucose intolerance  
4  
5 at the first pregnancy visit are diagnosed as having type 2 diabetes (not GDM).<sup>2</sup> In Victoria in  
6  
7 2008, 6.1% of all women giving birth had diabetes in pregnancy (personal communication, A  
8  
9 Cooper, Perinatal Data Collection Unit). At the planned original study sites, the Royal Women's  
10  
11 Hospital (RWH) and Mercy Hospital for Women (MHW), 7.7% (495/6443) and 10.3%  
12  
13 (690/5748) of women respectively giving birth in 2009 had diabetes in pregnancy.  
14  
15  
16  
17  
18  
19

20 Pregnancies affected by diabetes have increased risk of perinatal complications, including  
21  
22 increased perinatal mortality for infants of women with type 1 diabetes.<sup>6-8</sup> In gestational diabetes,  
23  
24 poorer glycaemic control is also associated with adverse infant outcomes.<sup>9</sup>  
25  
26  
27  
28

29 Infants of women with diabetes in pregnancy are at increased risk of hypoglycaemia (secondary  
30  
31 to hyperinsulinism) and other morbidities in the early neonatal period (e.g. macrosomia,  
32  
33 respiratory distress syndrome, prematurity, congenital anomalies, polycythaemia, jaundice).<sup>5, 10</sup>  
34  
35 They are more likely to themselves develop diabetes, and have an increased risk of obesity later  
36  
37 in life.<sup>5</sup>  
38  
39  
40  
41  
42

43 A strategy to decrease the risk of these infants developing diabetes or impaired glucose tolerance  
44  
45 later in life would be one way of interrupting the cycle of diabetes. One such strategy is to  
46  
47 increase the rate of exclusive breastfeeding from birth in these infants, given that early exposure  
48  
49 to cow's milk protein increases the incidence of both type 1 (juvenile onset) and later onset type  
50  
51 2 diabetes.<sup>11-13</sup> However, infants of women with diabetes are at high risk of not being exclusively  
52  
53 breastfed for a number of reasons. Studies have found generally that women with diabetes are  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 less likely to breastfeed than other women, and likely to breastfeed for a shorter duration,<sup>14-17</sup>  
4  
5 although one study has found that where breastfeeding is encouraged and supported, women with  
6  
7 diabetes can be just as successful as women without diabetes.<sup>18</sup>  
8  
9

10  
11  
12 Lactogenesis II, the onset of copious milk production, usually occurs 30 to 40 hours after birth.<sup>19</sup>  
13  
14 Women with diabetes experience up to a 24 hour delay in lactogenesis II compared to women  
15  
16 without diabetes,<sup>20-24</sup> as do women with glucose intolerance, increasing their infants' risk of  
17  
18 receiving infant formula.<sup>25</sup> Women with diabetes are also at risk of other co-morbidities, most  
19  
20 commonly obesity.<sup>26, 27</sup> In turn, obese women<sup>28</sup> and obese women with diabetes<sup>29</sup> are less likely  
21  
22 to successfully breastfeed. Separation of mother and infant following caesarean birth (also more  
23  
24 likely in women with diabetes in pregnancy<sup>27, 30</sup>) and/or admission to special and neonatal  
25  
26 intensive care units (SCN/NICU), further decreases the likelihood of establishing  
27  
28 breastfeeding.<sup>31, 32</sup>  
29  
30  
31  
32  
33  
34  
35

36 Since infants of women with diabetes are at increased risk of hypoglycaemia<sup>10</sup> they require blood  
37  
38 glucose monitoring and are often admitted to the SCN. If infants are hypoglycaemic and their  
39  
40 mother is unable to provide a sufficient volume of expressed breast milk in addition to  
41  
42 breastfeeding, they may receive supplementation with infant formula or intravenous glucose.  
43  
44 This has led to a practice whereby some women with diabetes in pregnancy are being advised to  
45  
46 express breast milk before their infant's birth.  
47  
48  
49  
50

### 51 52 53 **Current practice** 54 55 56 57 58 59 60

1  
2  
3 Increasing numbers of maternity providers are encouraging pregnant women with diabetes to  
4 express and store breast milk (colostrum) in the last weeks before their expected delivery date,<sup>33-</sup>  
5  
6  
7  
8  
9  
10  
11  
12  
13 Some organisations have implemented guidelines for antenatal expressing of colostrum,<sup>39, 40</sup> and  
14  
15 in a recent book for consumers, there is a section entitled “Getting a head start: expressing milk  
16  
17 before your baby is born”.<sup>41, p. 57</sup> This practice pre-supposes that establishing a supply of  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Increasing numbers of maternity providers are encouraging pregnant women with diabetes to express and store breast milk (colostrum) in the last weeks before their expected delivery date,<sup>33-</sup><sup>38</sup> so that breast milk is available in the postpartum period, thereby possibly avoiding infant formula if neonatal hypoglycaemia needs management with supplementary formula feeding. Some organisations have implemented guidelines for antenatal expressing of colostrum,<sup>39, 40</sup> and in a recent book for consumers, there is a section entitled “Getting a head start: expressing milk before your baby is born”.<sup>41, p. 57</sup> This practice pre-supposes that establishing a supply of colostrum pre-birth might ameliorate: i) the number of infants of women with diabetes who receive infant formula or intravenous glucose if supplementary feeding is required to treat neonatal hypoglycaemia (stored colostrum could be used); ii) the delay in lactogenesis II in women with diabetes; and iii) the number of infants of women with diabetes admitted to the SCN. These recommendations for practice have not been investigated and are therefore theoretical, and there is very limited evidence regarding the safety or efficacy of encouraging antenatal expressing of breast milk.

### **The evidence**

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

A retrospective cohort study from the UK included 94 women, and found that infants of women with diabetes who expressed were born one week earlier on average (37.1 weeks (SD 2.6), compared to 38.2 weeks (SD 2.2),  $p = 0.06$ ), and were more likely to be admitted to the SCN.<sup>42</sup> We conducted a pilot study in 2007 that also provided some evidence, and provided the baseline data to undertake the proposed randomised controlled trial (RCT).<sup>43</sup> We recruited 43 women with diabetes in pregnancy who agreed to undertake antenatal expressing (35% of those eligible agreed to participate when invited) and we conducted a concurrent audit of clinical outcomes in a

1  
2  
3 group of infants of similar women (with diabetes in pregnancy) to provide 'control' data.  
4  
5 Women in the expressing pilot completed a demographic questionnaire, were then taught how to  
6  
7 express colostrum, and encouraged to do so for ten minutes twice daily from 36 weeks gestation.  
8  
9 They were advised on the safe storage of colostrum, which they froze for their baby's use after  
10  
11 birth. Women kept a diary documenting their expressing and completed telephone interviews at 6  
12  
13 and 12 weeks postpartum. We found that 30% of infants in the pilot were admitted to SCN  
14  
15 compared with 17% of 'control' infants, and that reasons for admission to SCN were similar in  
16  
17 the two groups.<sup>43</sup> Intravenous glucose use was 14% for pilot infants and 8% for control infants  
18  
19 (RR 1.77; 95% CI 0.63, 4.96). There was no evidence of any fetal compromise based on  
20  
21 cardiocographs (CTGs) undertaken after the first expressing episode. Women recorded blood  
22  
23 sugar levels (BSLs) following their first three expressing episodes. Although the median BSLs  
24  
25 were normal and suggested no evidence of hypoglycaemia at a group level, 10% (2/20) of  
26  
27 women had a BSL < 3.5 mmol/L after the first expressing episode, and seven women (27%;  
28  
29 7/29) reported they experienced tightenings or Braxton Hicks contractions as a result of antenatal  
30  
31 expressing, and one ceased the intervention for this reason.  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 The amount of colostrum women obtained varied according to number of expressions, length of  
42  
43 time between onset of expressing and birth and the time spent expressing, with a median of 14  
44  
45 days expressing and 40 ml (range 5 to 310 ml) obtained. Although some women found  
46  
47 expressing difficult (31%), the intervention was positively received overall, and 95% (38/40) of  
48  
49 women would express antenatally again if proven beneficial. More infants in the pilot received  
50  
51 exclusive breast milk during their postpartum hospital stay (37%) compared to the 'control'  
52  
53 group (27%) (RR 1.38; 95% CI 0.82, 2.31).  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 In January 2010, we conducted a telephone survey of 48 tertiary and large metropolitan and  
7 regional maternity hospitals across Australia providing care for 109,465 births per year and  
8 found that 30 of these services (63%; 65,478 births) recommend antenatal milk expressing.<sup>44</sup> Of  
9 these, 21 (70%) recommended antenatal expressing primarily to women with diabetes in  
10 pregnancy (although the practice is also being recommended to women with other high risk  
11 pregnancies), and 11 (37%) had a policy or guideline for antenatal milk expressing. Across the  
12 11 services with a policy or guideline for antenatal milk expressing, the mean gestation  
13 recommended for commencement of expressing was 36 weeks (range 30-37 weeks). Of the 18  
14 services (38%; 43987 births) who *did not* recommend this practice, five (28%) discontinued  
15 antenatal expressing based on the recommendations of our pilot observational study,<sup>43</sup> and await  
16 evidence to inform this practice.<sup>44</sup>  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 A recent Cochrane review identified no RCTs that investigated the practice of expressing and  
35 storing breast milk during pregnancy, and concluded that there is no high level systematic  
36 evidence to inform the safety and efficacy of this practice.<sup>38</sup> Rigorous evidence is urgently  
37 required to inform the clinical practice of antenatal expression of colostrum.<sup>44</sup> This paper  
38 describes the protocol for an adequately powered RCT exploring the practice of advising women  
39 with diabetes in pregnancy to express breast milk from 36 weeks gestation.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 METHODS

53  
54

55 A multi-centre, two arm, unblinded RCT design will be used to compare the practice of antenatal  
56 milk expressing with standard care, for women with pre-existing or gestational diabetes. In the  
57  
58  
59  
60

1  
2  
3 original trial design we included only women with diabetes in pregnancy who required insulin,  
4  
5 choosing this group because they are the women for whom antenatal expressing is most often  
6  
7 suggested, yet are at the highest risk of perinatal complications, particularly if glycaemic control  
8  
9 is poor. This inclusion criterion changed, as detailed below in the sample size section.  
10  
11

## 12 13 **Aims**

### 14 15 *Primary aim:*

16  
17 To establish whether the practice of antenatal expressing of colostrum from 36 weeks gestation,  
18  
19 for women with diabetes in pregnancy, increases the proportion of infants who require admission  
20  
21 to the SCN or NICU compared with the infants of similar women receiving standard care.  
22  
23  
24

### 25 26 27 *Primary hypothesis:*

28  
29 Infants of women with diabetes in pregnancy who commence antenatal expressing of colostrum  
30  
31 from 36 weeks gestation will be more likely to be admitted to the SCN or NICU during the  
32  
33 primary hospitalisation after birth compared with the infants of women with diabetes in  
34  
35 pregnancy receiving standard care.  
36  
37  
38

### 39 40 41 *Secondary aims:*

42  
43 To determine whether antenatal expressing of colostrum from 36 weeks gestation for women  
44  
45 with diabetes in pregnancy, compared with similar women receiving standard care:  
46  
47

- 48  
49 a) *increases* the proportion of infants receiving exclusive breast milk at three months of age (i.e.  
50  
51 is effective in promoting exclusive breastfeeding);  
52  
53  
54 b) *decreases* the mean gestation at birth (i.e. is harmful);  
55  
56  
57  
58  
59  
60

c) *increases* the proportion of infants receiving exclusive breast milk during initial hospital stay  
(i.e. is effective).

We will also:

- d) Test the cost and cost effectiveness of this intervention compared with standard care;
- e) Explore the views and experiences of women participating in this trial; and
- f) Collect data on other outcomes – e.g. fetal well-being associated with expressing; volumes of antenatal colostrum obtained; time to onset of lactogenesis II (onset of copious milk production).

Table 1 summarises the potential harms and benefits of antenatal expressing of colostrum.

**Table 1: Potential harms and benefits of antenatal breast milk expressing**

Potential harms	Potential benefits
Increased admissions to SCN/NICU (shows increased neonatal morbidity and mother-infant separation)	Increased exclusive breastfeeding during initial hospital stay
Decreased mean duration of pregnancy	Increased exclusive breastfeeding at 3 months postpartum
Increased requirement for IV glucose	Increased duration of any breastfeeding
	Improved maternal satisfaction
	Decreased risk of subsequent diabetes for the infant*

### Study sample

All eligible women booking for maternity care at the trial sites during the recruitment period will be offered study participation.

*Inclusion criteria:* Any woman:

- (1) with pre-existing or gestational diabetes
- (2) between 34 and 36 weeks gestation (but not more than 37 weeks);
- (3) with a singleton pregnancy in a cephalic presentation;
- (4) attending the study sites for pregnancy care as a public patient;

(5) planning to breastfeed; and

(6) able to speak and read in English.

Exclusion criteria: Women with:

(1) any history of antepartum haemorrhage, or placenta praevia (even in the absence of any antenatal bleeding);

(2) an unknown or classical caesarean section scar or more than one lower segment caesarean section scar;

(3) any suspicion of fetal compromise including known or suspected intrauterine growth restriction, documented macrosomia (estimated fetal weight  $\geq 95^{\text{th}}$  percentile) with abdominal circumference  $> 97^{\text{th}}$  centile, polyhydramnios or any abnormal tests of fetal well-being (whether clinically, ultrasound or CTG based); or

(4) a known fetal anomaly.

(5) Hypertension and proteinuria - if any concerns about fetal wellbeing

(6) A serious maternal mental health issue, other severe maternal obstetric/medical issue.

In some sites there are small proportions of infants who are automatically admitted to the SCN after birth, e.g. infants of women who have Type 1 or Type 2 diabetes, or women on higher doses of insulin. In these sites, given the primary outcome is SCN/NICU admission; the women in those groups will be ineligible for inclusion in the trial.

## Recruitment

Eligible women will be identified and offered participation by a study midwife at 34-36 weeks gestation, to maximise the opportunity to recruit women. If the woman is interested she will provide written consent and complete a questionnaire regarding demographic details and breastfeeding intentions. Randomisation occurs at 36 weeks gestation, so recruitment and

1  
2  
3 randomisation will often be a two stage process. Prior to randomisation women will have a  
4 preliminary 20 minute CTG, and if the CTG is assessed as reactive and without significant  
5 uterine activity, the woman will be randomised to one of the two trial arms. Women allocated to  
6 the intervention will be taught hand expressing at that time (detailed more fully below), with a  
7 CTG during this first 10 minute expressing episode and for 20 minutes after. The schedule of  
8 participant enrollment, intervention and assessments is shown in Figure 1.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Randomisation procedure**

21  
22 Randomisation is stratified by site, first baby or not, and diabetes type (i.e. pre-existing (Type 1  
23 or Type 2), gestational requiring insulin, or gestational not requiring insulin). A computerised  
24 random number generator was used to select random permuted blocks with at least three  
25 different block sizes. A system designed and administered by the Clinical Epidemiology and  
26 Biostatistics Unit at Murdoch Childrens Research Institute is accessed by the internet to ascertain  
27 women's allocation.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **The intervention**

40  
41 Women randomised to the intervention will *receive all standard advice and care* (guided by  
42 existing hospital protocols) *as well as* receiving instructions on the intervention. They will be  
43 taught how to hand express colostrum (Supplementary file 1). Women will be encouraged to  
44 express twice daily for *no more* than ten minutes until being admitted to hospital to give birth,  
45 unless any concerns arise which indicate that the intervention should cease (see below).  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 Women will be provided with written and verbal instructions on the safe storage and  
56 transportation of colostrum (Supplementary file 1). Expressed colostrum will be labelled with the  
57  
58  
59  
60

1  
2  
3 woman's hospital medical record number and kept in syringes in her home freezer. Women will  
4  
5 be asked to bring the frozen colostrum in an 'esky' (cold storage box) when they are admitted for  
6  
7 the birth. Women will be provided with all the equipment they require for this intervention:  
8  
9 syringes (2 and 5 ml), small eskies, ice pack and specimen bags, labels with medical record  
10  
11 number, and diaries to document each episode of expressing.  
12  
13  
14

15  
16  
17 A dedicated freezer will be available at each trial site for storage of antenatally expressed frozen  
18  
19 colostrum. Midwifery and neonatal staff will receive education about the trial and be informed as  
20  
21 to where to store the frozen expressed breast milk.  
22  
23  
24

## 25 **Ensuring maternal and fetal well-being**

### 26 *Surveillance in hospital*

27  
28  
29 Women in the intervention group will undertake an expressing episode under CTG surveillance  
30  
31 at the time they are taught expressing (immediately after randomisation). If a woman requires  
32  
33 further CTG's during their pregnancy care she will be asked to do one of her expressing episodes  
34  
35 during those CTGs, as the uterus may become more sensitive to the resultant oxytocin surge with  
36  
37 advancing gestation. The protocol for subsequent CTGs and expressing will be identical to that  
38  
39 of the initial expressing episode i.e. preliminary CTG, express for ten minutes, then continue the  
40  
41 CTG for 20 minutes post-expression. The CTG must be reactive prior to commencing  
42  
43 expressing. Immediate discontinuation of expressing will occur if there are any signs of fetal  
44  
45 compromise (fetal tachycardia, reduced variability, late decelerations), or if there is excessive  
46  
47 uterine activity (either a hypertonic contraction (one lasting longer than 90 seconds), or  
48  
49 tachysystole (> 5 contractions per 10 minute period)). Each participating centre will follow their  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 existing protocol for management of fetal distress, including availability of acute tocolysis and  
4  
5 on-site obstetric support.  
6  
7

### 8 9 10 *Surveillance at home*

11  
12 Women will be advised of precautions related to expressing in the antenatal period and informed  
13 that if they have concerns regarding any of these issues they should telephone the study midwife,  
14  
15 or the Emergency Department/Birth suite of their relevant hospital after hours. Instructions will  
16  
17 be given regarding the importance of:  
18  
19

- 20 1. Noting normal fetal activity prior to expressing.
- 21 2. Reporting any complications after expressing, such as excessive uterine activity, vaginal  
22 blood loss, decreased fetal movements, or signs of hypoglycaemia.
- 23 3. Measuring BSLs after the first three episodes of expressing, to ensure that the expressing is  
24 not causing hypoglycaemia (which can occur with breastfeeding).<sup>45</sup> A consultant endocrinologist  
25 will advise the research team on maternal diabetes care as needed, and assist with interpretation  
26 of relevant outcomes.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Standard care**

40  
41 All women with pre-existing or gestational diabetes are seen by a Diabetes Educator for  
42 management of their diabetes. Additionally, all women discuss breastfeeding with midwives  
43 during pregnancy, and at all sites women can ask to see a lactation consultant in the antenatal  
44 period if they wish. No site can participate in the trial if they recommend that women express  
45 colostrum in the antenatal period.  
46  
47  
48  
49  
50  
51  
52

### 53 54 55 **Management of neonatal hypoglycaemia**

1  
2  
3 The intervention being tested is not aimed at preventing hypoglycaemia, however in practice the  
4 aim of many clinicians who advise antenatal milk expressing for this group is to avoid the use of  
5 formula for supplementary feeding if/when neonatal hypoglycaemia occurs. Based on our pilot  
6 data, approximately half of the admissions to SCN or NICU will be for neonatal  
7 hypoglycaemia.<sup>43</sup> We will measure the incidence and duration of neonatal hypoglycaemia;  
8 however it is not expected that encouraging women to express prior to birth could of itself  
9 prevent neonatal hypoglycaemia.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 Existing guidelines for management of newborn infants at risk of hypoglycaemia, including  
23 infants of women with diabetes in pregnancy, will be followed. While there may be slight  
24 variations in guidelines by trial site, for the purposes of data analysis neonatal hypoglycaemia is  
25 defined as a true blood glucose (TBG) < 2.6 mmol/L as measured on a blood gas analyser (or  
26 portable point of care TBG analyser) or in the laboratory. Sites whose guidelines for  
27 management of newborn infants at risk of hypoglycaemia are too different from this are not  
28 eligible to participate in the trial, and site guidelines are reviewed by the trial neonatologist prior  
29 to a decision about any site's suitability for inclusion. Although bedside testing with a  
30 glucometer is possible (providing BSLs), this method is not accurate at low blood glucose levels,  
31 when a TBG is mandatory. Prompt, standardised and accurate blood glucose measurement of  
32 TBG is optimal,<sup>46, 47</sup> and in the trial will eliminate measurement bias in either trial arm. A  
33 portable point of care TBG analyser will facilitate prompt, accurate TBG measurement at the  
34 bedside without separation of mother and baby – crucial in supporting early breastfeeding.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Stratification by site ensures that any slight variation in infant glucose management will not  
4 affect trial outcomes. Regardless of group assignment, mothers will breastfeed their infants, and  
5 express their milk postpartum if required. The first response to hypoglycaemia (as per existing  
6 clinical guidelines at the two primary trial sites, RWH and MHW) is a prescribed volume (30-60  
7 ml/kg/day of supplemental feed of expressed breast milk or infant formula, or glucose gel  
8 (0.5mL/kg of 40%) massaged into buccal mucosa. Hypoglycaemia unresponsive to supplemental  
9 feeding triggers admission to SCN/NICU, more frequent, larger supplemental feeds, further  
10 glucose gel or IV glucose therapy, to achieve normal TBGs.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Process evaluation**

26 Adherence to the study protocol and intervention fidelity will be monitored.

27  
28 (1) *Measures of intervention exposure:* Women in the intervention group will keep a diary of  
29 antenatal expressing, noting: date and time of day each expressing episode takes place, length of  
30 each expressing episode, and volume of colostrum expressed. Women in the control group will  
31 be asked at the 1 to 2 week interview if they expressed antenatally, to check for any cross-over.  
32  
33

34 (2) Monthly meetings with all project staff will include discussion of protocol adherence,  
35 measurement and documentation.  
36  
37

38 (3) Intervention evaluation by participants: The telephone interview at twelve weeks postpartum  
39 will include questions regarding women's views and experiences of being in the trial.  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Sample size**

50 Given the aim of antenatal expressing of breast milk is to benefit infants of women with diabetes  
51 in pregnancy, we debated whether our primary outcome should test efficacy or safety. Because  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 our pilot data suggested potential harm, we chose the primary hypothesis to test safety. We are  
4  
5 also powered to test the listed secondary outcomes.  
6  
7

8  
9 *Primary outcome:*

10  
11 As mentioned above, when we designed the trial originally, we included only women with  
12  
13 diabetes in pregnancy who required insulin, and our sample size calculations were based on  
14  
15 estimates of this group. With that population we needed an estimated sample size of 658 women  
16  
17 (329 in each group) based on 80% power (alpha 0.05), and allowing 5% loss to follow up. This  
18  
19 allowed the detection of an increase in the proportion of infants of women (requiring insulin in  
20  
21 pregnancy) who are admitted to SCN or NICU in the primary hospital admission following birth,  
22  
23 from 20% in the control group to 30% in the intervention group. This estimate was derived from  
24  
25 the pilot and audit data presented above.  
26  
27  
28  
29  
30  
31

32  
33 *Secondary outcomes:*

34  
35 This sample size also allows detection of:

- 36  
37 (a) a difference in exclusive breastfeeding at 3 months of 12% (40% in the control group  
38  
39 compared with 52% in the intervention group) (assuming the infants in the intervention achieve  
40  
41 the same rate as the state-wide data and as per our pilot, i.e. 52%) (requires n=254);  
42  
43 (b) a difference in the mean duration of pregnancy (38 weeks in the control group compared with  
44  
45 37 weeks in the intervention group) (requires n=184; means, SDs derived from Soltani study<sup>42</sup>);  
46  
47 and  
48  
49 (c) a difference in exclusive breastfeeding during initial hospital stay of 12% (25% in the control  
50  
51 group compared with 37% in the intervention group).  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Sample size revision May 2012*

Recruitment to the trial as per the original criteria commenced in July 2011. In May 2012 it was agreed to amend our inclusion criteria to include all women with diabetes in pregnancy. This was due to two factors a) the slow recruitment rate due to smaller numbers of eligible women than anticipated, and b) expert advice from outside the research group recommending that the external validity of the trial would be increased if the criteria were broadened to also include women with diabetes in pregnancy who did not require insulin.

The change of inclusion criteria meant that a baseline rate of admission to the SCN or NICU would be 17% rather than 20% as per our original sample size calculations (based on a review of all 2011 outcome data for women with diabetes in pregnancy at the RWH). We undertook various recalculations to address this. Regarding the sample size with the altered baseline:

- to detect 10% absolute difference (as in the original calculation) we would need 289 per group – this would be a decrease in sample size – which none of the team considered optimal;
- to detect a 50% relative increase to 25.7% would need 379 per group, i.e. 758 (100 more than current sample of 658) – again this is not ideal as the study is not funded for this and we did not use this difference in our original calculations;
- or we could maintain current sample size (658) and describe the study power to detect a 10% absolute difference.

The final option was chosen, i.e. we agreed to maintain the current sample size and assume increased power to detect 10% absolute difference. Allowing for 5% loss to follow up, the

1  
2  
3 original sample size of 658 would provide 625 women at primary outcome measurement. This  
4  
5 would detect a change in primary outcome from 17% to 27% with a power of 85%. All the  
6  
7 original secondary outcome comparisons described above will be maintained given the sample  
8  
9 size has not altered.  
10  
11

### 12 13 14 **Outcome variables**

#### 15 16 *Primary outcome:*

17  
18 Proportion of infants admitted to SCN or NICU.  
19  
20  
21  
22

#### 23 24 *Secondary outcomes:*

- 25  
26
- 27 a) Proportion of infants receiving exclusive breast milk at three months of age ;
  - 28  
29 b) Gestational age at birth;
  - 30  
31 c) Proportion of infants receiving exclusive breast milk during initial hospital stay;
  - 32  
33 d) Cost of the intervention to hospitals and to women and cost effectiveness against  
34  
35 breastfeeding outcomes;
  - 36  
37 e) Women's views and experiences;
  - 38  
39 f) Fetal wellbeing associated with expressing (assessed by CTG at initial then subsequent  
40  
41 opportunistic CTG episodes); antenatal expression episodes, timing and volumes collected  
42  
43 (intervention group only); time to lactogenesis II.  
44  
45  
46  
47  
48  
49

#### 50 51 *Potential explanatory variables:*

- 52  
53 g) Reasons for SCN/NICU admissions;  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45
- h) Hypoglycaemia treatments in maternity or SCN/NICU including glucose gel, IV glucose, glucagon, hydrocortisone;
  - i) Length of time until three consecutive infant TBG levels  $\geq 2.6$  mmol/L;
  - j) Maternal blood glucose levels following first three expressing episodes;
  - k) Maternal morbidity that could be related to expressing e.g. premature labour.

## 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### Maternal and infant

*Demographic data* (including age, education, marital status, ethnic background, smoking) will be collected by questionnaire at recruitment, prior to randomisation.

*Obstetric/neonatal medical outcomes* will be abstracted from the medical record following the birth by researchers blinded to group allocation.

*Other outcome data* will be collected by telephone administered questionnaire at 1-2 and 12 weeks postpartum. Women in the intervention arm will complete a diary of their expressing activity.

### Economic evaluation

Resource use data will be collected from the medical record following birth and from women's self-reported use of health care and other resources in the 12 weeks after the birth. Costs included in the economic evaluation are those relating to care provided by the hospital (including admission to SCN/NICU) and women's (infants') use of health care and other societal resources

1  
2  
3 over the period of the evaluation. Measured resource use will be valued using existing unit cost  
4 estimates (e.g., Diagnosis Related Groups cost weights for hospital admissions for mother and  
5 infant<sup>48</sup> and Medicare fee schedules for any attendances at the women's local doctor).<sup>49</sup> As the  
6 primary outcome measure is itself a resource use item, economic evaluation will be expressed as  
7 cost-effectiveness analysis against exclusive breastfeeding at three months.  
8  
9  
10  
11  
12  
13

14  
15  
16  
17 **Blinding:** The nature of the trial necessitates non-blinding of participants assigned to the  
18 intervention group, so that staff know to look for expressed breast milk in the freezer if it is  
19 available and required, and at most sites both the intervention and control groups need to be non-  
20 blinded to ensure that point of care TBGs are performed rather than BSLs, as most sites do BSLs  
21 unless indicated (rather than the TBGs required by this trial). Staff at sites that routinely  
22 undertake TBGs for all infants of women with diabetes in pregnancy will be blinded to women in  
23 the control group. Abstraction of medical record data will be undertaken blinded to group  
24 allocation; data will be presented to the data monitoring committee for the interim analysis in  
25 unlabelled study groups; and the research team will remain blinded to group allocation at all  
26 stages prior to final data analysis.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 **Data analysis**

44  
45 Data will be collected to meet the CONSORT guidelines for reporting of randomised trials,<sup>50</sup>  
46 including data on eligible non-participants. The first stage of analysis will check the  
47 comparability of participants allocated to the two groups. The intervention group will be  
48 compared with the standard care group by intention to treat analysis. The primary outcome  
49 measure will be compared using chi-square tests and odds ratios. Comparison of means will be  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 undertaken for continuous variables using t-tests where data are normally distributed or Mann-  
4  
5 Whitney U tests will compare medians otherwise. Ranked or Likert-type scales will be analysed  
6  
7 using cumulative odds ratios. Where there are differences in baseline characteristics of the  
8  
9 women in the two groups which might be associated with outcomes, an additional multivariate  
10  
11 analysis will be carried out. Duration of breastfeeding will be compared using Kaplan-Meier  
12  
13 statistics. Content analysis will be used to summarise open-ended comments.<sup>51</sup>  
14  
15  
16  
17  
18  
19

20 Research Ethics approval will be sought from La Trobe University and all participating hospitals.  
21  
22  
23

24 **Data and Safety Monitoring Committees:** A Data Monitoring Committee including a  
25  
26 statistician, a midwife and an obstetrician (experienced in conducting RCTs) will undertake an  
27  
28 interim analysis after half the women have given birth. A Safety Committee including a  
29  
30 neonatologist, a midwife and an obstetrician (all experienced clinicians and researchers) will  
31  
32 review reports of any adverse events, e.g. an excess of any of the predefined adverse events for  
33  
34 women or infants, blinded to group allocation (see Supplementary file 2 for list of events). Terms  
35  
36 of reference for each of these committees will guide frequency of reviews and the conditions  
37  
38 under which either committee would advise the research team that enrolment to the trial should  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## DISCUSSION

This will be the first study to provide rigorous evidence regarding the practice of antenatal expression of colostrum in late pregnancy for women with diabetes in pregnancy. It will explore the safety and efficacy for mother, fetus and infant.

1  
2  
3  
4  
5  
6 There remains widespread national and international interest in the outcomes of this trial, and the  
7  
8 controversy can be seen in a recent review which concluded antenatal expressing should be  
9  
10 encouraged: “Although Forster et al.<sup>43</sup> have argued the teaching of [antenatal expressing] should  
11  
12 cease until the practice is proven to be safe and effective ... an ethical dilemma now exists ... as  
13  
14 to whether the benefits of early colostrum feedings in at-risk babies outweighs the unproven side  
15  
16 effect of premature labour.<sup>52</sup> In the absence of evidence, the clear benefits of early feedings of  
17  
18 colostrum should outweigh the unsupported risks of ceasing [antenatal expressing] education.”<sup>53</sup>  
19  
20  
21  
22  
23  
24  
25

## 26 TRIAL STATUS

27  
28  
29 Approval has been granted from the following Human Research Ethics Committees (reference  
30  
31 number in brackets): Royal Women’s Hospital (11/07); Mercy Hospital for Women (11/06 ); La  
32  
33 Trobe University (11-004); Monash Medical Centre (12181-B); Barwon Health (13/06);  
34  
35 Peninsula Health (14/PH/21).  
36  
37  
38  
39  
40  
41

42 Recruitment commenced at Royal Women’s Hospital in June 2011, followed by Mercy Hospital  
43  
44 for Women in July 2011. In May 2012, due to a) the slow recruitment rate resulting from low  
45  
46 numbers of eligible women, and b) external expert advice to include women with diabetes in  
47  
48 pregnancy who did *not* require insulin, thereby increasing the trial’s external validity, it was  
49  
50 agreed to amend our inclusion criteria to include *all* women with diabetes in pregnancy (not just  
51  
52 those requiring insulin) and to identify and recruit further trial sites. Monash Medical Centre  
53  
54 commenced in October 2012 and Barwon Health (Geelong Hospital) in April 2013. The last site,  
55  
56  
57  
58  
59  
60



1  
2  
3 Frankston Hospital, had ethics approval from Peninsula Health in July 2014 and recruitment will  
4  
5 commence soon.  
6  
7  
8  
9  
10

11  
12  
13 In the original protocol women who had a history of spontaneous preterm birth or who had  
14  
15 threatened preterm birth in the current pregnancy were excluded, however following the Safety  
16  
17 Committee review of the first 100 births, which found no evidence of contractions following  
18  
19 expressing, and because no woman is randomised prior to 36 weeks gestation, this exclusion  
20  
21 criterion was removed.  
22  
23  
24  
25  
26

### 27 **Monitoring CTGs**

28  
29 The CTGS for all of the first 100 women who have given birth (pre-randomisation, during and  
30  
31 post-expressing) have been assessed by investigator SPW, with no sign of fetal compromise or  
32  
33 increase in contractions as a result of expressing.  
34  
35  
36  
37  
38

### 39 **Sub-studies**

- 40  
41  
42 1. *Onset of lactation.* In order to determine if the onset of lactation is delayed in women  
43  
44 with diabetes, we are recruiting a comparison group of 200 women without diabetes.  
45  
46 Women are being recruited in the postnatal wards at the Royal Women's Hospital in  
47  
48 2014, and followed by telephone at 1 to 2 weeks postpartum, using identical questions to  
49  
50 the DAME interview.  
51  
52  
53 2. *Antenatal colostrum.* We plan to conduct a biochemical analysis of some excess samples  
54  
55 of antenatal colostrum that infants have not required.  
56  
57  
58  
59  
60

## ACKNOWLEDGEMENTS

We are grateful to all the trial sites for their support of the DAME trial. We also thank the women and their babies participating in this trial.

## COMPETING INTERESTS

None.

## FUNDING

This trial is funded by a project grant from the National Health and Medical Council of Australia (no. 1005345). We have also received equipment grants from the National Health and Medical Council of Australia.

## AUTHORS' CONTRIBUTIONS

Authors: Della A Forster (DAF), Susan Jacobs (SJ), Lisa H Amir (LHA), Peter Davis (PD), Susan P Walker (SPW), Kerri McEgan (KMc), Gillian Opie (GO), Susan M Donath (SMD), Anita M Moorhead (AMM), Rachael Ford (RF), Catharine McNamara (CMc), Amanda Aylward(AA), Lisa Gold (LG)

DAF, AMM, and KMc conceptualised the study, and SJ, LHA, PD, SPW, GO, SMD, RF, CMc, AA and LG contributed to study design. DAF, LHA, AMM, KMc drafted protocol and all

1  
2  
3 authors contributed to protocol revision and application of grant. DAF, LHA, AMM developed  
4 data collection tools and all authors contributed to refinement, piloting and completion of tools.  
5  
6  
7  
8 AMM, KMc, LHA, GO, SJ, and DAF piloted and refined the intervention. AMM, DAF, AA, and  
9  
10 CMc developed the recruitment processes. DAF, AMM, and LHA developed the data collection  
11  
12 process. DAF and LHA drafted the trial protocol manuscript, and all authors read and  
13  
14 contributed to drafts, and read and approved final manuscript.  
15  
16  
17  
18

## 19 REFERENCES

- 21 1 Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in  
22 Australia in the new millennium: measuring health loss from diseases, injuries and risk factors.  
23 *Med J Aust* 2008;188:36-40.
- 24 2 American Diabetes Association. Diagnosis and classification of diabetes mellitus.  
25 *Diabetes Care* 2010;33 Suppl 1:S62-9.
- 26 3 Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a  
27 history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin*  
28 *Endocrinol Metab* 2008;93:4774-9.
- 29 4 Australian Institute of Health and Welfare. Diabetes prevalence in Australia: an  
30 assessment of national data sources. Canberra; 2009.
- 31 5 Mitanchez D, Burguet A, Simeoni U. Infants born to mothers with gestational diabetes  
32 mellitus: mild neonatal effects, a long-term threat to global health. *J Pediatr* 2014;164:445-50.
- 33 6 Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for  
34 mild gestational diabetes. *N Engl J Med* 2009;361:1339-48.
- 35 7 Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious  
36 adverse pregnancy outcome in 933 women with type 1 diabetes. *Diabetes Care* 2009;32:1046-8.
- 37 8 Garcia-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin  
38 requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of  
39 direction. *Diabetologia* 2010;53:446-51.
- 40 9 HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia  
41 and adverse pregnancy outcomes. *N Engl J Med* 2008;358:1991-2002.
- 42 10 Mitanchez D. Foetal and neonatal complications in gestational diabetes: perinatal  
43 mortality, congenital malformations, macrosomia, shoulder dystocia, birth injuries, neonatal  
44 complications. *Diabetes Metab* 2010;36:617-27.
- 45 11 Cardwell CR, Stene LC, Ludvigsson J, et al. Breast-feeding and childhood-onset type 1  
46 diabetes: A pooled analysis of individual participant data from 43 observational studies. *Diabetes*  
47 *Care* 2012;35:2215-25.
- 48 12 Patelarou E, Girvalaki C, Brokalaki H, Patelarou A, Androulaki Z, Vardavas C. Current  
49 evidence on the associations of breastfeeding, infant formula, and cow's milk introduction with  
50 type 1 diabetes mellitus: a systematic review. *Nutr Rev* 2012;70:509-19.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 13 Ip S, Chung M, Raman G, et al. Breastfeeding and Maternal and Infant Health Outcomes in Developed Countries. Rockville, MD: Agency for Healthcare Research and Quality; 2007 April 2007.
- 14 Webster J, Moore K, McMullan A. Breastfeeding outcomes for women with insulin dependent diabetes. *J Hum Lact* 1995;11:195-200.
- 15 Hummel S, Winkler C, Schoen S, et al. Breastfeeding habits in families with Type 1 diabetes. *Diabet Med* 2007;24:671-6.
- 16 Schoen S, Sichert-Hellert W, Hummel S, Ziegler AG, Kersting M. Breastfeeding duration in families with type 1 diabetes compared to non-affected families: results from BABYDIAB and DONALD studies in Germany. *Breastfeed Med* 2008;3:171-75.
- 17 Finkelstein SA, Keely E, Feig DS, Tu X, Yasseen AS, 3rd, Walker M. Breastfeeding in women with diabetes: lower rates despite greater rewards. A population-based study. *Diabet Med* 2013.
- 18 Stage E, Norgard H, Damm P, Mathiesen E. Long-term breast-feeding in women with type 1 diabetes. *Diabetes Care* 2006;29:771-4.
- 19 Kulski JK, Smith M, Hartmann PE. Perinatal concentrations of progesterone, lactose and alpha-lactalbumin in the mammary secretion of women. *J Endocrinol* 1977;74:509-10.
- 20 Murtaugh MA, Ferris AM, Capacchione CM, Reece EA. Energy intake and glycemia in lactating women with type 1 diabetes. *J Am Diet Assoc* 1998;98:642-8.
- 21 Arthur PG, Kent JC, Hartmann PE. Metabolites of lactose synthesis in milk from diabetic and nondiabetic women during lactogenesis II. *J Pediatr Gastroenterol Nutr* 1994;19:100-08.
- 22 Bitman J, Hamosh M, Hamosh P, et al. Milk composition and volume during the onset of lactation in a diabetic mother. *Am J Clin Nutr* 1989;50:1364-69.
- 23 Miyake A, Tahara M, Koike K, Tanizawa O. Decrease in neonatal suckled milk volume in diabetic women. *Eur J Obstet Gynecol Reprod Biol* 1989;33:49-53.
- 24 Neubauer SH, Ferris AM, Chase CG, et al. Delayed lactogenesis in women with insulin-dependent diabetes mellitus. *Am J Clin Nutr* 1993;58:54-60.
- 25 Nommsen-Rivers LA, Dolan LM, Huang B. Timing of stage II lactogenesis is predicted by antenatal metabolic health in a cohort of primiparas. *Breastfeed Med* 2012;7:43-9.
- 26 Hawkins JS, Casey BM. Labor and delivery management for women with diabetes. *Obstet Gynecol Clin N Am* 2007;34:323-34.
- 27 Beucher G, Viaris de Lesegno B, Dreyfus M. Maternal outcome of gestational diabetes mellitus. *Diabetes Metab* 2010;36:522-37.
- 28 Amir LH, Donath S. A systematic review of maternal obesity and breastfeeding intention, initiation and duration. *BMC Pregnancy Childbirth* 2007;7:9.
- 29 Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. *Diabetes Care* 2006;29:1105-07.
- 30 Remsberg KE, McKeown RE, McFarland KF, Irwin LS. Diabetes in pregnancy and cesarean delivery. *Diabetes Care* 1999;22:1561-7.
- 31 Simmons D, Conroy C, Thompson CF. In-hospital breast feeding rates among women with gestational diabetes and pregestational Type 2 diabetes in South Auckland. *Diabetic Med* 2005;22:177-81.
- 32 Renfrew M, Craig D, Dyson L, et al. Breastfeeding promotion for infants in neonatal units: a systematic review and economic analysis. *Health Technol Assess* 2009;13:1-146.

- 1  
2  
3 33 Cox SG. Expressing and storing colostrum antenatally for use in the newborn period.  
4 *Breastfeed Rev* 2006;14:11-6.  
5  
6 34 Rietveld C. Antenatal colostrum harvesting for pregnant women with diabetes mellitus  
7 (DM) (Poster). Midwifery Conference. New Zealand, 2011.  
8 35 Chapman T, Pincombe J, Harris M, Fereday J. Antenatal breast expression: exploration  
9 and extent of teaching practices amongst International Board Certified Lactation Consultant  
10 midwives across Australia. *Women Birth* 2013;26:41-8.  
11 36 Brisbane JM, Giglia RC. Experiences of expressing and storing colostrum antenatally: A  
12 qualitative study of mothers in regional Western Australia. *J Child Health Care* Published online  
13 first: 23 Oct 2013; doi 10.1177/1367493513503586.  
14 37 Tozier PK. Colostrum versus formula supplementation for glucose stabilization in  
15 newborns of diabetic mothers. *JOGGN* 2013;42:619-26.  
16 38 East CE, Dolan WJ, Forster DA. Antenatal breast milk expression by women with  
17 diabetes for improving infant outcomes. *Cochrane Database Syst Rev* 2014;7:CD010408.  
18 39 Cairns and Hinterland Health Service District. Antenatal expression of colostrum  
19 procedure: Queensland Government; 2008.  
20 40 Logan Hospital, Women's and Children's Health Service. Breastfeeding Information for  
21 Pregnant Women with Diabetes. 2009.  
22 41 West D, Marasco L. Getting your milk supply off to a good start. The Breastfeeding  
23 Mother's Guide to Making More Milk. New York: McGraw-Hill, 2009;57-67.  
24 42 Soltani H, Scott AM. Antenatal breast expression in women with diabetes: outcomes  
25 from a retrospective cohort study. *Int Breastfeed J* 2012;7:18.  
26 43 Forster DA, McEgan K, Ford R, et al. Diabetes and antenatal milk expressing: a pilot  
27 project to inform the development of a randomised controlled trial. *Midwifery* 2011;27:209-14.  
28 44 Forster DA, Amir LH, Moorhead A, et al. Is *not* testing a major change in clinical  
29 practice an ethical dilemma? (Letter). *Midwifery* 2011;27:e301-2.  
30 45 Lawrence RA, Lawrence RM. Diabetes mellitus. Breastfeeding: A Guide For The  
31 Medical Profession. 5th ed. St Louis: Mosby, 1999;515-21.  
32 46 Ho HT, Yeung WK, Young BW. Evaluation of "point of care" devices in the  
33 measurement of low blood glucose in neonatal practice. *Arch Dis Child Fetal Neonatal Ed*  
34 2004;89:F356-9.  
35 47 Bonacruz GL, Arnold JD, Leslie GI, Wyndham L, Koumantakis G. Survey of the  
36 definition and screening of neonatal hypoglycaemia in Australia. *J Paediatr Child Health*  
37 1996;32:299-301.  
38 48 Australian Government Department of Health and Ageing. National Hospital Cost Data  
39 Collection, Cost Weights for AR-DRG version 6.0x, Round 14 (2009-10). Canberra; 2012.  
40 49 Australian Government Department of Health and Ageing. Medical Benefits Schedule  
41 Book. Canberra; 2011.  
42 50 Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for  
43 reporting parallel group randomised trials. *PLoS Med* 2010;7:e1000251.  
44 51 Ezzy D. Coding data and interpreting text: methods of analysis. *Qualitative Analysis:  
45 Practice and Innovation*. Sydney: Allen & Unwin, 2002;81-110.  
46 52 Cox S. An ethical dilemma: should recommending antenatal expressing and storing of  
47 colostrum continue? *Breastfeed Rev* 2010;18:5-7.  
48 53 Chapman T, Pincombe J, Harris M. Antenatal breast expression: a critical review of the  
49 literature. *Midwifery* 2013;29:203-10.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure**

**Figure 1: SPIRIT Figure**

For peer review only

Figure 1. Schedule of enrolment, intervention, and assessments for the DAME (Diabetes and Antenatal Expressing) trial

TIMEPOINT	Enrolment	Allocation	Post-allocation				Close-out
	34-36 weeks of pregnancy	36 weeks of pregnancy	Allocation	Admission for birth	1-2 weeks postpartum	12 weeks postpartum	$t_x$
<b>ENROLMENT:</b>							
Eligibility screen	X						
Informed consent	X						
CTG	X						
Allocation		X					
<b>INTERVENTIONS:</b>							
<i>Hand expressing twice/day for 10 mins</i>			←→				
<b>ASSESSMENTS:</b>							
<i>Maternal characteristics (in person)</i>	X						
<i>Maternal expressing diary (intervention group)</i>			←→				
<i>Obstetric data (abstracted from medical record)</i>							X
<i>Neonatal data (abstracted from medical record)</i>							X
<i>Infant feeding and onset of lactation data (telephone)</i>					X		
<i>Infant feeding data (telephone)</i>						X	
<i>Economic data</i>							X

CTG: cardiotocograph



## Instructions for hand expressing and storage of colostrum (early breast milk) for the Diabetes & Antenatal Milk Expressing (DAME) trial

As part of the DAME trial you have been allocated to begin expressing colostrum (early breast milk) from 36 weeks of pregnancy. This information sheet will answer some questions you may have about expressing and storing your breast milk at home.

### How often do I express and for how long?

- Express twice a day, e.g. once in the morning, once in the evening.
- Express for about 10 minutes in total per session, for about 5 minutes each breast.
- If there is little or no colostrum expressed – don't worry, it is normal for women to produce varying amounts of colostrum.
- After you have expressed each time, and once you have stored your expressed colostrum, record the date and time you expressed in the expressing diary we have given you. Include the amount of colostrum you obtained as well as how long you expressed and any other comments you want to add.

### How do I collect and store the colostrum?

- You have been given syringes to collect the colostrum.
- You may find it easier to collect the colostrum onto a clean teaspoon. Wash the teaspoon first with hot soapy water, then draw the colostrum up from the teaspoon into the syringe for storage (or pour into one of the small pots if you have a larger amount).
- You can use one syringe to collect all your colostrum for 24 hours, but always use a new syringe or pot each day. If you need to use more than one syringe or pot per day then ensure **all** are labelled.
- Place the stopper on the end of the syringe before storing it in the refrigerator or freezing.
- Label the syringes with the labels we have given you. The labels include your name, your hospital number and your date of birth. You will need to **add** the date and time of the first colostrum expressed in to any syringe (so you will have a new label with your details on each 24 hours).
- Place each syringe/pot into the freezer within 24 hours of first using it to store the colostrum. In other words, you can store your expressed milk in the refrigerator for up to 24 hours, and keep adding to it during this time, but then it needs to be frozen.

### How do I hand express?

Before you start, always wash your hands with warm water and soap. You may find expressing after a warm bath or shower helps with the flow of colostrum. Sometimes gentle massage of your breasts before expressing may help. The DAME research midwife will have shown you how to express, but the instructions are here as well.

- Place the pads of your thumb and forefinger opposite each other on the outer edge of your areola and then gently press them back in to your breast tissue and squeeze together rhythmically. This should not be painful.
- Move your fingers around the areola to express all the milk ducts (like moving around the face of a clock).
- Express until the flow stops (up to 5 minutes, but not more) then change to the other breast.
- If your hand tires, swap to the other hand or have a rest.
- Remember – do not worry if there is little or no colostrum.
- Contact the DAME midwife if you need any further expressing advice.



### What should I look out for?

Hand expressing while you are pregnant may cause an increase of the hormone oxytocin in your blood. This may cause some tightenings (mild contractions) in your uterus. In accordance with your usual care as a pregnant woman with diabetes, you may be having monitoring of your baby's heart rate (CTG monitoring). After the first expressing session in hospital you can continue twice daily expressing at home. If you have any monitoring of your baby's heart rate we ask you to do one of your daily expressings during the monitoring so we can make sure everything is going well and write that in the expressing record book we have given you .

It is unlikely that expressing will cause any problems, however before you express at home it is important that:

- You are not experiencing any abdominal or labour pains; and
- Your baby is moving normally.

If you are not sure that your baby is moving normally, you should not express and you should contact the Emergency Department (which is the same as we tell all pregnant women).

### If you notice any of the following things during or after expressing:

- A prolonged tightening (lasting more than 1 minute);
- Very frequent tightenings (more than 5 in 10 minutes);
- Any bleeding; or
- A reduction in the baby's movements;

You should stop expressing and contact Emergency Department for advice.

### Do I monitor my blood sugar whilst expressing?

- Today we have checked your blood sugar level following the first time you expressed
- For the next two times you express (at home) please check your blood sugar level and record it in your expressing diary as well as where you usually record it (e.g. your blood glucose record) Do this after you have expressed and at the same time as you would normally check do a blood sugar check, for example, start expressing about half an hour before your blood sugar level is due. This will reduce the need for extra blood testing.
- Treat any abnormal blood sugar level reading as you would do normally. That is, contact the Diabetes Educator or Emergency Department if you are concerned.

### What happens when I come in to hospital to have my baby?

- Bring your frozen colostrum in with you when you come in to hospital to have your baby.
- Please bring it in the esky we gave you, packed with a frozen cold pack (there was one with the esky we gave you).
- Give the esky to the midwife when you arrive at the hospital and tell her it contains your frozen colostrum.
- It will be stored in the freezer in Ward 4 East (in the milk room).

### Contact numbers:

**Emergency Department The Womens' Hospital**

**03 8345 3636**

**DAME Research Midwife/Coordinator**

**03 8345 2932**

**Diabetes Educator**

**03 8345 2153**



## Diabetes and Antenatal Milk Expressing (DAME) Trial

ACTRN12611000217909

### SAFETY COMMITTEE TERMS OF REFERENCE

The purpose of this document is to describe the roles and responsibilities of the Safety Committee for the DAME trial including the timing of meetings, methods of providing information to and from the Safety Committee, frequency and format of meetings and relationships with other committees.

#### Aims

To safeguard the interests of trial participants by assessing the safety of participation, and to assist and advise the principal investigators so as to protect the credibility of the trial.

#### Relationships

The Safety Committee reports to the DAME principal investigators. A Data Monitoring Committee will be reporting separately on recruitment progress and accruing data from the trial.

#### Specific roles of the Safety Committee

- To review reports of serious adverse outcomes in both trial arms to identify possible contributing factors related to participation in the trial and any association with either trial arm
- To advise the principal investigators if the Safety Committee has concerns about the safety of participants that might require the trial's early termination

The adverse events that the Safety Committee will be required to report on are:

- Perinatal/infant outcomes
  - Fetal compromise associated with expressing as evidenced by:
    - a) any abnormality on any a CTG during/following expressing (within four hours); or
    - b) decreased fetal movements during/following expressing (within four hours) necessitating presentation to hospital for fetal monitoring and/or cessation of the intervention;
  - Moderate to severe encephalopathy with or without seizures;
  - Admission to NICU/NISC for respiratory support (defined as respiratory support greater than four hours);
  - Perinatal death.
- Maternal
  - Maternal hypoglycaemia within half an hour of expressing (defined by a blood glucose level less than 4 mmol/l or symptoms requiring treatment<sup>1</sup>)
  - Abdominal pain after antenatal expressing –within 4 hours
  - Vaginal bleeding after antenatal expressing –within 4 hours

---

<sup>1</sup> Women will have received a list of symptoms of hypoglycaemia as part of their pregnancy care, and those defined by Diabetes Australia, Victoria are weakness, trembling or shaking, sweating, light headedness, headache, lack of concentration/behaviour change, dizziness, tearful/crying, Irritability, numbness around the lips and fingers, hunger.

# BMJ Open

## Safety and efficacy of antenatal milk expressing for women with diabetes in pregnancy: protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006571.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Oct-2014
Complete List of Authors:	Amir, Lisa; La Trobe University, Judith Lumley Centre Forster, Della; Royal Women's Hospital, Maternity; La Trobe University, Judith Lumley Centre Jacobs, Susan; Royal Women's Hospital, Neonatal Services Davis, Peter; Royal Women's Hospital, Neonatal Services Walker, Susan; University of Melbourne, Obstetrics and Gynaecology McEgan, Kerri; Mercy Hospital for Women, Opie, Gillian; Mercy Hospital for Women, Donath, Susan; Murdoch Childrens Research Institute, Clinical Epidemiology and Biostatistics Unit Moorhead, Anita; Royal Women's Hospital, Maternity; La Trobe University, Judith Lumley Centre Ford, Rachel; Royal Women's Hospital, Maternity McNamara, Catherine; Mercy Hospital for Women, Diabetes in pregnancy Aylward, Amanda; Royal Women's Hospital, Diabetes Education Gold, Lisa; Deakin University, Deakin Health Economics
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Paediatrics, Diabetes and endocrinology, Nutrition and metabolism
Keywords:	Diabetes in pregnancy < DIABETES & ENDOCRINOLOGY, NEONATOLOGY, Maternal medicine < OBSTETRICS, NUTRITION & DIETETICS

SCHOLARONE™  
Manuscripts

# Safety and efficacy of antenatal milk expressing for women with diabetes in pregnancy: protocol for a randomised controlled trial

Della A Forster<sup>1,2\*</sup>, Susan Jacobs<sup>2,3,4</sup>, Lisa H Amir<sup>1</sup>, Peter Davis<sup>2</sup>, Susan P. Walker<sup>4,5</sup>, Kerri McEgan<sup>5</sup>, Gillian Opie<sup>4,5</sup>, Susan M Donath<sup>6</sup>, Anita M. Moorhead<sup>1,2</sup>, Rachael Ford<sup>1,2</sup>, Catharine McNamara<sup>5</sup>, Amanda Aylward<sup>2</sup>, Lisa Gold<sup>7</sup>

## Author affiliations

<sup>1</sup>Judith Lumley Centre (formerly Mother & Child Health Research), La Trobe University, 215 Franklin Street, Melbourne, Victoria 3000, Australia

<sup>2</sup>Royal Women's Hospital, 20 Flemington Rd, Parkville, Victoria 3052, Australia

<sup>3</sup>Clinical Sciences, Murdoch Childrens Research Institute, PO Box 911, Parkville Victoria 3052, Australia

<sup>4</sup>Department of Obstetrics and Gynaecology, University of Melbourne, Victoria 3010, Australia

<sup>5</sup>Mercy Hospital for Women, 163 Studley Road, Heidelberg, Victoria 3084, Australia

<sup>6</sup>Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research Institute, PO Box 911, Parkville Victoria 3052, Australia

<sup>7</sup>Deakin Health Economics, Deakin University, Burwood, Victoria 3125, Australia

## \*Corresponding author:

Prof Della Forster  
Judith Lumley Centre  
La Trobe University  
Level 3  
215 Franklin St  
Melbourne VIC 3000  
AUSTRALIA

Word count, excluding title page and abstract: 5490

References: 52

Figures: 1

Tables 1

## ABSTRACT

### Introduction

Many maternity providers recommend that women with diabetes in pregnancy express and store breast milk in late pregnancy so breast milk is available after birth, given 1) infants of these women are at increased risk of hypoglycaemia in the first 24 hours of life; and 2) the delay in lactogenesis II compared to women without diabetes that increases their infant's risk of receiving infant formula.

The Diabetes and Antenatal Milk Expressing (DAME) trial will establish whether advising women with diabetes in pregnancy (pre-existing or gestational) to express breast milk from 36 weeks gestation increases the proportion of infants who require admission to special or neonatal intensive care units (SCN/NICU) compared with infants of women receiving standard care.

Secondary outcomes include birth gestation, breastfeeding outcomes and economic impact.

### Methods and analysis

Women will be recruited from 34 weeks gestation to a multi-centre, two arm, unblinded randomised controlled trial. The intervention commences at 36 weeks. Randomisation will be stratified by site, parity and diabetes type. Women allocated to the intervention will be taught expressing and encouraged to hand express twice daily for ten minutes and keep an expressing diary. The sample size of 658 (329 per group) will detect a 10% difference in proportion of babies admitted to SCN/NICU (85% power, alpha 0.05). Data are collected at recruitment (structured questionnaire), after birth (abstracted from medical record blinded to group), and 2 and 12 weeks postpartum (telephone interview). *Data analysis:* the intervention group will be

1  
2  
3 compared with the standard care group by intention to treat analysis, and the primary outcome  
4  
5 compared using chi-square and odds ratios.  
6  
7  
8  
9

### 10 **Ethics and dissemination**

11  
12 Research ethics approval will be obtained from participating sites. Results will be published in  
13  
14 peer reviewed journals and presented to clinicians, policy makers and study participants.  
15  
16  
17  
18  
19

20 **Trial Registration:** Australian Controlled Trials Register ACTRN12611000217909  
21  
22  
23

### 24 **Keywords**

25  
26 breast milk, breastmilk, maternal diabetes, gestational diabetes, breastfeeding, randomised  
27  
28 controlled trial (RCT), antenatal expressing, hypoglycaemia, infant, newborn  
29

### 30 **Strengths and limitations of this study**

31  
32 This will be the first study to provide rigorous evidence regarding the practice of antenatal  
33  
34 expression of colostrum in late pregnancy for women with diabetes in pregnancy. It will explore  
35  
36 the safety and efficacy for mother, fetus and infant. The conclusions about antenatal expressing  
37  
38 will be restricted to women with diabetes in pregnancy, but if this practice is found to be safe and  
39  
40 effective for this high risk group, the conclusions are likely to be applicable to other women as  
41  
42 well.  
43  
44  
45  
46  
47  
48

## 49 **BACKGROUND**

50  
51  
52 Diabetes is the second highest contributor to loss of health in Australia.<sup>1</sup> Type 2 diabetes and  
53  
54 gestational diabetes (GDM) are increasing globally.<sup>2</sup> GDM occurs on average in 7% of  
55  
56 pregnancies (range 1 to 14% depending on the population characteristics and diagnostic tests  
57  
58  
59  
60

1  
2  
3 used),<sup>2</sup> and is the strongest single population predictor of type 2 diabetes.<sup>3</sup> An additional 1% of  
4  
5 females aged below 44 years have pre-existing diabetes (type 1 or 2),<sup>4</sup> with type 2 diabetes  
6  
7 increasing in women of childbearing age.<sup>5</sup> Since 2009, women found to have glucose intolerance  
8  
9 at the first pregnancy visit are diagnosed as having type 2 diabetes (not GDM).<sup>2</sup> In Victoria in  
10  
11 2008, 6.1% of all women giving birth had diabetes in pregnancy (personal communication, A  
12  
13 Cooper, Perinatal Data Collection Unit). At the planned original study sites, the Royal Women's  
14  
15 Hospital (RWH) and Mercy Hospital for Women (MHW), 7.7% (495/6443) and 10.3%  
16  
17 (690/5748) of women respectively giving birth in 2009 had diabetes in pregnancy.

18  
19  
20  
21  
22  
23  
24 Pregnancies affected by diabetes have increased risk of perinatal complications, including  
25  
26 increased perinatal mortality for infants of women with type 1 diabetes.<sup>6-8</sup> In gestational diabetes,  
27  
28 poorer glycaemic control is also associated with adverse infant outcomes.<sup>9</sup>

29  
30  
31  
32  
33  
34 Infants of women with diabetes in pregnancy are at increased risk of hypoglycaemia (secondary  
35  
36 to hyperinsulinism) and other morbidities in the early neonatal period (e.g. macrosomia,  
37  
38 respiratory distress syndrome, prematurity, congenital anomalies, polycythaemia, jaundice).<sup>5, 10</sup>  
39  
40 They are more likely to themselves develop diabetes, and have an increased risk of obesity later  
41  
42 in life.<sup>5</sup>

43  
44  
45  
46  
47  
48 A strategy to decrease the risk of these infants developing diabetes or impaired glucose tolerance  
49  
50 later in life would be one way of interrupting the cycle of diabetes. One such strategy is to  
51  
52 increase the rate of exclusive breastfeeding from birth in these infants, given that early exposure  
53  
54 to cow's milk protein increases the incidence of both type 1 (juvenile onset) and later onset type  
55  
56  
57  
58  
59  
60

1  
2  
3 2 diabetes.<sup>11-13</sup> However, infants of women with diabetes are at high risk of not being exclusively  
4 breastfed for a number of reasons. Studies have found generally that women with diabetes are  
5 less likely to breastfeed than other women, and likely to breastfeed for a shorter duration,<sup>14-17</sup>  
6 although one study has found that where breastfeeding is encouraged and supported, women with  
7 diabetes can be just as successful as women without diabetes.<sup>18</sup>  
8  
9  
10  
11  
12  
13

14  
15  
16  
17 Lactogenesis II, the onset of copious milk production, usually occurs 30 to 40 hours after birth.<sup>19</sup>  
18 Women with diabetes experience up to a 24 hour delay in lactogenesis II compared to women  
19 without diabetes,<sup>20-24</sup> as do women with glucose intolerance, increasing their infants' risk of  
20 receiving infant formula.<sup>25</sup> Women with diabetes are also at risk of other co-morbidities, most  
21 commonly obesity.<sup>26, 27</sup> In turn, obese women<sup>28</sup> and obese women with diabetes<sup>29</sup> are less likely  
22 to successfully breastfeed. Separation of mother and infant following caesarean birth (also more  
23 likely in women with diabetes in pregnancy<sup>27, 30</sup>) and/or admission to special and neonatal  
24 intensive care units (SCN/NICU), further decreases the likelihood of establishing  
25 breastfeeding.<sup>31, 32</sup>  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Since infants of women with diabetes are at increased risk of hypoglycaemia<sup>10</sup> they require blood  
42 glucose monitoring and are often admitted to the SCN. If infants are hypoglycaemic and their  
43 mother is unable to provide a sufficient volume of expressed breast milk in addition to  
44 breastfeeding, they may receive supplementation with infant formula or intravenous glucose.  
45  
46  
47  
48  
49

50 This has led to a practice whereby some women with diabetes in pregnancy are being advised to  
51 express breast milk before their infant's birth.  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Current practice

Increasing numbers of maternity providers are encouraging pregnant women with diabetes to express and store breast milk (colostrum) in the last weeks before their expected delivery date,<sup>33-38</sup> so that breast milk is available in the postpartum period, thereby possibly avoiding infant formula if neonatal hypoglycaemia needs management with supplementary formula feeding. Some organisations have implemented guidelines for antenatal expressing of colostrum,<sup>39, 40</sup> and in a recent book for consumers, there is a section entitled “Getting a head start: expressing milk before your baby is born”.<sup>41, p. 57</sup> This practice pre-supposes that establishing a supply of colostrum pre-birth might ameliorate: i) the number of infants of women with diabetes who receive infant formula or intravenous glucose if supplementary feeding is required to treat neonatal hypoglycaemia (stored colostrum could be used); ii) the delay in lactogenesis II in women with diabetes; and iii) the number of infants of women with diabetes admitted to the SCN. These recommendations for practice have not been investigated and are therefore theoretical, and there is very limited evidence regarding the safety or efficacy of encouraging antenatal expressing of breast milk.

## The evidence

A retrospective cohort study from the UK included 94 women, and found that infants of women with diabetes who expressed were born one week earlier on average (37.1 weeks (SD 2.6), compared to 38.2 weeks (SD 2.2),  $p = 0.06$ ), and were more likely to be admitted to the SCN.<sup>42</sup> We conducted a pilot study in 2007 that also provided some evidence, and provided the baseline data to undertake the proposed randomised controlled trial (RCT).<sup>43</sup> We recruited 43 women with diabetes in pregnancy who agreed to undertake antenatal expressing (35% of those eligible

1  
2  
3 agreed to participate when invited) and we conducted a concurrent audit of clinical outcomes in a  
4 group of infants of similar women (with diabetes in pregnancy) to provide 'control' data.  
5

6  
7  
8 Women in the expressing pilot completed a demographic questionnaire, were then taught how to  
9 express colostrum, and encouraged to do so for ten minutes twice daily from 36 weeks gestation.  
10  
11 They were advised on the safe storage of colostrum, which they froze for their baby's use after  
12 birth. Women kept a diary documenting their expressing and completed telephone interviews at 6  
13 and 12 weeks postpartum. We found that 30% of infants in the pilot were admitted to SCN  
14 compared with 17% of 'control' infants, and that reasons for admission to SCN were similar in  
15 the two groups.<sup>43</sup> Intravenous glucose use was 14% for pilot infants and 8% for control infants  
16 (RR 1.77; 95% CI 0.63, 4.96). There was no evidence of any fetal compromise based on  
17 cardiocotographs (CTGs) undertaken after the first expressing episode. Women recorded blood  
18 sugar levels (BSLs) following their first three expressing episodes. Although the median BSLs  
19 were normal and suggested no evidence of hypoglycaemia at a group level, 10% (2/20) of  
20 women had a BSL < 3.5 mmol/L after the first expressing episode, and seven women (27%;  
21 7/29) reported they experienced tightenings or Braxton Hicks contractions as a result of antenatal  
22 expressing, and one ceased the intervention for this reason.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The amount of colostrum women obtained varied according to number of expressions, length of  
44 time between onset of expressing and birth and the time spent expressing, with a median of 14  
45 days expressing and 40 ml (range 5 to 310 ml) obtained. Although some women found  
46 expressing difficult (31%), the intervention was positively received overall, and 95% (38/40) of  
47 women would express antenatally again if proven beneficial. More infants in the pilot received  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 exclusive breast milk during their postpartum hospital stay (37%) compared to the 'control'  
4  
5 group (27%) (RR 1.38; 95% CI 0.82, 2.31).  
6  
7  
8  
9

10 In January 2010, we conducted a telephone survey of 48 tertiary and large metropolitan and  
11 regional maternity hospitals across Australia providing care for 109,465 births per year and  
12 found that 30 of these services (63%; 65,478 births) recommend antenatal milk expressing.<sup>44</sup> Of  
13 these, 21 (70%) recommended antenatal expressing primarily to women with diabetes in  
14 pregnancy (although the practice is also being recommended to women with other high risk  
15 pregnancies), and 11 (37%) had a policy or guideline for antenatal milk expressing. Across the  
16 11 services with a policy or guideline for antenatal milk expressing, the mean gestation  
17 recommended for commencement of expressing was 36 weeks (range 30-37 weeks). Of the 18  
18 services (38%; 43987 births) who *did not* recommend this practice, five (28%) discontinued  
19 antenatal expressing based on the recommendations of our pilot observational study,<sup>43</sup> and await  
20 evidence to inform this practice.<sup>44</sup>  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 A recent Cochrane review identified no RCTs that investigated the practice of expressing and  
40 storing breast milk during pregnancy, and concluded that there is no high level systematic  
41 evidence to inform the safety and efficacy of this practice.<sup>38</sup> Rigorous evidence is urgently  
42 required to inform the clinical practice of antenatal expression of colostrum.<sup>44</sup> This paper  
43 describes the protocol for an adequately powered RCT exploring the practice of advising women  
44 with diabetes in pregnancy to express breast milk from 36 weeks gestation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## 56 METHODS

57  
58  
59  
60

1  
2  
3 A multi-centre, two arm, unblinded RCT design will be used to compare the practice of antenatal  
4 milk expressing with standard care, for women with pre-existing or gestational diabetes. In the  
5 original trial design we included only women with diabetes in pregnancy who required insulin,  
6 choosing this group because they are the women for whom antenatal expressing is most often  
7 suggested, yet are at the highest risk of perinatal complications, particularly if glycaemic control  
8 is poor. This inclusion criterion changed, as detailed below in the sample size section.  
9  
10  
11  
12  
13  
14  
15  
16

## 17 18 **Aims**

### 19 20 *Primary aim:*

21 To establish whether the practice of antenatal expressing of colostrum from 36 weeks gestation,  
22 for women with diabetes in pregnancy, increases the proportion of infants who require admission  
23 to the SCN or NICU compared with the infants of similar women receiving standard care.  
24  
25  
26  
27  
28  
29  
30  
31

### 32 33 *Primary hypothesis:*

34 Infants of women with diabetes in pregnancy who commence antenatal expressing of colostrum  
35 from 36 weeks gestation will be more likely to be admitted to the SCN or NICU during the  
36 primary hospitalisation after birth compared with the infants of women with diabetes in  
37 pregnancy receiving standard care.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 47 *Secondary aims:*

48 To determine whether antenatal expressing of colostrum from 36 weeks gestation for women  
49 with diabetes in pregnancy, compared with similar women receiving standard care:  
50  
51

52 a) *increases* the proportion of infants receiving exclusive breast milk at three months of age (i.e.  
53 is effective in promoting exclusive breastfeeding);  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 b) *decreases* the mean gestation at birth (i.e. is harmful);  
4  
5 c) *increases* the proportion of infants receiving exclusive breast milk during initial hospital stay  
6  
7 (i.e. is effective).  
8  
9

10  
11  
12 We will also:

- 13  
14  
15 d) Test the cost and cost effectiveness of this intervention compared with standard care;  
16  
17 e) Explore the views and experiences of women participating in this trial; and  
18  
19 f) Collect data on other outcomes – e.g. fetal well-being associated with expressing; volumes of  
20  
21 antenatal colostrum obtained; time to onset of lactogenesis II (onset of copious milk production).  
22  
23  
24  
25  
26

27 Table 1 summarises the potential harms and benefits of antenatal expressing of colostrum.  
28  
29  
30  
31

32 **Table 1: Potential harms and benefits of antenatal breast milk expressing**  
33

Potential harms	Potential benefits
Increased admissions to SCN/NICU (shows increased neonatal morbidity and mother-infant separation)	Increased exclusive breastfeeding during initial hospital stay Increased exclusive breastfeeding at 3 months postpartum Increased duration of any breastfeeding
Decreased mean duration of pregnancy	Improved maternal satisfaction
Increased requirement for IV glucose	Decreased risk of subsequent diabetes for the infant*

34  
35  
36  
37  
38  
39  
40  
41  
42  
43 **Study sample**

44 All eligible women booking for maternity care at the trial sites during the recruitment period will  
45  
46 be offered study participation.  
47  
48

49 *Inclusion criteria:* Any woman:

- 50  
51 (1) with pre-existing or gestational diabetes  
52  
53 (2) between 34 and 36 weeks gestation (but not more than 37 weeks);  
54  
55 (3) with a singleton pregnancy in a cephalic presentation;  
56  
57  
58  
59  
60

1  
2  
3 (4) attending the study sites for pregnancy care as a public patient;  
4  
5

6 (5) planning to breastfeed; and  
7

8 (6) able to speak and read in English.  
9

10 Exclusion criteria: Women with:  
11

12 (1) any history of antepartum haemorrhage, or placenta praevia (even in the absence of any  
13 antenatal bleeding);  
14

15 (2) an unknown or classical caesarean section scar or more than one lower segment caesarean  
16 section scar;  
17

18 (3) any suspicion of fetal compromise including known or suspected intrauterine growth  
19 restriction, documented macrosomia (estimated fetal weight  $\geq$  95<sup>th</sup> percentile) with abdominal  
20 circumference  $>$  97<sup>th</sup> centile, polyhydramnios or any abnormal tests of fetal well-being (whether  
21 clinically, ultrasound or CTG based); or  
22

23 (4) a known fetal anomaly.  
24

25 (5) Hypertension and proteinuria - if any concerns about fetal wellbeing  
26

27 (6) A serious maternal mental health issue, other severe maternal obstetric/medical issue.  
28

29 In some sites there are small proportions of infants who are automatically admitted to the SCN  
30 after birth, e.g. infants of women who have Type 1 or Type 2 diabetes, or women on higher  
31 doses of insulin. In these sites, given the primary outcome is SCN/NICU admission; the women  
32 in those groups will be ineligible for inclusion in the trial.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **Recruitment**

51 Eligible women will be identified and offered participation by a study midwife at 34-36 weeks  
52 gestation, to maximise the opportunity to recruit women. If the woman is interested she will  
53 provide written consent and complete a questionnaire regarding demographic details and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 breastfeeding intentions. Randomisation occurs at 36 weeks gestation, so recruitment and  
4  
5 randomisation will often be a two stage process. Prior to randomisation women will have a  
6  
7 preliminary 20 minute CTG, and if the CTG is assessed as reactive and without significant  
8  
9 uterine activity, the woman will be randomised to one of the two trial arms. Women allocated to  
10  
11 the intervention will be taught hand expressing at that time (detailed more fully below), with a  
12  
13 CTG during this first 10 minute expressing episode and for 20 minutes after. The schedule of  
14  
15 participant enrollment, intervention and assessments is shown in Figure 1.  
16  
17  
18  
19

### 20 21 22 **Randomisation procedure**

23  
24 Randomisation is stratified by site, first baby or not, and diabetes type (i.e. pre-existing (Type 1  
25  
26 or Type 2), gestational requiring insulin, or gestational not requiring insulin). A computerised  
27  
28 random number generator was used to select random permuted blocks with at least three  
29  
30 different block sizes. A system designed and administered by the Clinical Epidemiology and  
31  
32 Biostatistics Unit at Murdoch Childrens Research Institute is accessed by the internet to ascertain  
33  
34 women's allocation.  
35  
36  
37  
38  
39

### 40 41 **The intervention**

42  
43 Women randomised to the intervention will *receive all standard advice and care* (guided by  
44  
45 existing hospital protocols) *as well as* receiving instructions on the intervention. They will be  
46  
47 taught how to hand express colostrum (Supplementary file 1). Women will be encouraged to  
48  
49 express twice daily for *no more* than ten minutes until being admitted to hospital to give birth,  
50  
51 unless any concerns arise which indicate that the intervention should cease (see below).  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Women will be provided with written and verbal instructions on the safe storage and  
4  
5 transportation of colostrum (Supplementary file 1). Expressed colostrum will be labelled with the  
6  
7 woman's hospital medical record number and kept in syringes in her home freezer. Women will  
8  
9 be asked to bring the frozen colostrum in an 'esky' (cold storage box) when they are admitted for  
10  
11 the birth. Women will be provided with all the equipment they require for this intervention:  
12  
13 syringes (2 and 5 ml), small eskies, ice pack and specimen bags, labels with medical record  
14  
15 number, and diaries to document each episode of expressing.  
16  
17  
18  
19  
20

21  
22 A dedicated freezer will be available at each trial site for storage of antenatally expressed frozen  
23  
24 colostrum. Midwifery and neonatal staff will receive education about the trial and be informed as  
25  
26 to where to store the frozen expressed breast milk.  
27  
28  
29

### 30 **Ensuring maternal and fetal well-being**

#### 31 *Surveillance in hospital*

32  
33 Women in the intervention group will undertake an expressing episode under CTG surveillance  
34  
35 at the time they are taught expressing (immediately after randomisation). If a woman requires  
36  
37 further CTG's during their pregnancy care she will be asked to do one of her expressing episodes  
38  
39 during those CTGs, as the uterus may become more sensitive to the resultant oxytocin surge with  
40  
41 advancing gestation. The protocol for subsequent CTGs and expressing will be identical to that  
42  
43 of the initial expressing episode i.e. preliminary CTG, express for ten minutes, then continue the  
44  
45 CTG for 20 minutes post-expression. The CTG must be reactive prior to commencing  
46  
47 expressing. Immediate discontinuation of expressing will occur if there are any signs of fetal  
48  
49 compromise (fetal tachycardia, reduced variability, late decelerations), or if there is excessive  
50  
51 uterine activity (either a hypertonic contraction (one lasting longer than 90 seconds), or  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 tachysystole (> 5 contractions per 10 minute period)). Each participating centre will follow their  
4  
5 existing protocol for management of fetal distress, including availability of acute tocolysis and  
6  
7 on-site obstetric support.  
8  
9

### 10 11 12 *Surveillance at home*

13  
14  
15 Women will be advised of precautions related to expressing in the antenatal period and informed  
16  
17 that if they have concerns regarding any of these issues they should telephone the study midwife,  
18  
19 or the Emergency Department/Birth suite of their relevant hospital after hours. Instructions will  
20  
21 be given regarding the importance of:  
22  
23

- 24 1. Noting normal fetal activity prior to expressing.
- 25 2. Reporting any complications after expressing, such as excessive uterine activity, vaginal  
26  
27 blood loss, decreased fetal movements, or signs of hypoglycaemia.
- 28 3. Measuring BSLs after the first three episodes of expressing, to ensure that the expressing is  
29  
30 not causing hypoglycaemia (which can occur with breastfeeding).<sup>45</sup> A consultant endocrinologist  
31  
32 will advise the research team on maternal diabetes care as needed, and assist with interpretation  
33  
34 of relevant outcomes.  
35  
36  
37  
38  
39

### 40 41 42 **Standard care**

43  
44 All women with pre-existing or gestational diabetes are seen by a Diabetes Educator for  
45  
46 management of their diabetes. Additionally, all women discuss breastfeeding with midwives  
47  
48 during pregnancy, and at all sites women can ask to see a lactation consultant in the antenatal  
49  
50 period if they wish. No site can participate in the trial if they recommend that women express  
51  
52 colostrum in the antenatal period.  
53  
54  
55  
56  
57  
58  
59  
60

### Management of neonatal hypoglycaemia

The intervention being tested is not aimed at preventing hypoglycaemia, however in practice the aim of many clinicians who advise antenatal milk expressing for this group is to avoid the use of formula for supplementary feeding if/when neonatal hypoglycaemia occurs. Based on our pilot data, approximately half of the admissions to SCN or NICU will be for neonatal hypoglycaemia.<sup>43</sup> We will measure the incidence and duration of neonatal hypoglycaemia; however it is not expected that encouraging women to express prior to birth could of itself prevent neonatal hypoglycaemia.

Existing guidelines for management of newborn infants at risk of hypoglycaemia, including infants of women with diabetes in pregnancy, will be followed. While there may be slight variations in guidelines by trial site, for the purposes of data analysis neonatal hypoglycaemia is defined as a true blood glucose (TBG) < 2.6 mmol/L as measured on a blood gas analyser (or portable point of care TBG analyser) or in the laboratory. Sites whose guidelines for management of newborn infants at risk of hypoglycaemia are too different from this are not eligible to participate in the trial, and site guidelines are reviewed by the trial neonatologist prior to a decision about any site's suitability for inclusion. Although bedside testing with a glucometer is possible (providing BSLs), this method is not accurate at low blood glucose levels, when a TBG is mandatory. Prompt, standardised and accurate blood glucose measurement of TBG is optimal,<sup>46, 47</sup> and in the trial will eliminate measurement bias in either trial arm. A portable point of care TBG analyser will facilitate prompt, accurate TBG measurement at the bedside without separation of mother and baby – crucial in supporting early breastfeeding.

1  
2  
3 Stratification by site ensures that any slight variation in infant glucose management will not  
4 affect trial outcomes. Regardless of group assignment, mothers will breastfeed their infants, and  
5 express their milk postpartum if required. The first response to hypoglycaemia (as per existing  
6 clinical guidelines at the two primary trial sites, RWH and MHW) is a prescribed volume (30-60  
7 ml/kg/day of supplemental feed of expressed breast milk or infant formula, or glucose gel  
8 (0.5mL/kg of 40%) massaged into buccal mucosa. Hypoglycaemia unresponsive to supplemental  
9 feeding triggers admission to SCN/NICU, more frequent, larger supplemental feeds, further  
10 glucose gel or IV glucose therapy, to achieve normal TBGs.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Process evaluation**

26 Adherence to the study protocol and intervention fidelity will be monitored.

27  
28 (1) *Measures of intervention exposure:* Women in the intervention group will keep a diary of  
29 antenatal expressing, noting: date and time of day each expressing episode takes place, length of  
30 each expressing episode, and volume of colostrum expressed. Women in the control group will  
31 be asked at the 1 to 2 week interview if they expressed antenatally, to check for any cross-over.  
32  
33

34 (2) Monthly meetings with all project staff will include discussion of protocol adherence,  
35 measurement and documentation.  
36  
37

38 (3) Intervention evaluation by participants: The telephone interview at twelve weeks postpartum  
39 will include questions regarding women's views and experiences of being in the trial.  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Sample size**

50 Given the aim of antenatal expressing of breast milk is to benefit infants of women with diabetes  
51 in pregnancy, we debated whether our primary outcome should test efficacy or safety. Because  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 our pilot data suggested potential harm, we chose the primary hypothesis to test safety. We are  
4  
5 also powered to test the listed secondary outcomes.  
6  
7

8  
9 *Primary outcome:*

10  
11 As mentioned above, when we designed the trial originally, we included only women with  
12  
13 diabetes in pregnancy who required insulin, and our sample size calculations were based on  
14  
15 estimates of this group. With that population we needed an estimated sample size of 658 women  
16  
17 (329 in each group) based on 80% power (alpha 0.05), and allowing 5% loss to follow up. This  
18  
19 allowed the detection of an increase in the proportion of infants of women (requiring insulin in  
20  
21 pregnancy) who are admitted to SCN or NICU in the primary hospital admission following birth,  
22  
23 from 20% in the control group to 30% in the intervention group. This estimate was derived from  
24  
25 the pilot and audit data presented above.  
26  
27  
28  
29  
30  
31

32  
33 *Secondary outcomes:*

34  
35 This sample size also allows detection of:

- 36  
37 (a) a difference in exclusive breastfeeding at 3 months of 12% (40% in the control group  
38  
39 compared with 52% in the intervention group) (assuming the infants in the intervention achieve  
40  
41 the same rate as the state-wide data and as per our pilot, i.e. 52%) (requires n=254);  
42  
43 (b) a difference in the mean duration of pregnancy (38 weeks in the control group compared with  
44  
45 37 weeks in the intervention group) (requires n=184; means, SDs derived from Soltani study<sup>42</sup>);  
46  
47 and  
48  
49 (c) a difference in exclusive breastfeeding during initial hospital stay of 12% (25% in the control  
50  
51 group compared with 37% in the intervention group).  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Sample size revision May 2012*

Recruitment to the trial as per the original criteria commenced in July 2011. In May 2012 it was agreed to amend our inclusion criteria to include all women with diabetes in pregnancy. This was due to two factors a) the slow recruitment rate due to smaller numbers of eligible women than anticipated, and b) expert advice from outside the research group recommending that the external validity of the trial would be increased if the criteria were broadened to also include women with diabetes in pregnancy who did not require insulin.

The change of inclusion criteria meant that a baseline rate of admission to the SCN or NICU would be 17% rather than 20% as per our original sample size calculations (based on a review of all 2011 outcome data for women with diabetes in pregnancy at the RWH). We undertook various recalculations to address this. Regarding the sample size with the altered baseline:

- to detect 10% absolute difference (as in the original calculation) we would need 289 per group – this would be a decrease in sample size – which none of the team considered optimal;
- to detect a 50% relative increase to 25.7% would need 379 per group, i.e. 758 (100 more than current sample of 658) – again this is not ideal as the study is not funded for this and we did not use this difference in our original calculations;
- or we could maintain current sample size (658) and describe the study power to detect a 10% absolute difference.

The final option was chosen, i.e. we agreed to maintain the current sample size and assume increased power to detect 10% absolute difference. Allowing for 5% loss to follow up, the

1  
2  
3 original sample size of 658 would provide 625 women at primary outcome measurement. This  
4  
5 would detect a change in primary outcome from 17% to 27% with a power of 85%. All the  
6  
7 original secondary outcome comparisons described above will be maintained given the sample  
8  
9 size has not altered.  
10  
11

### 12 13 14 **Outcome variables**

#### 15 16 *Primary outcome:*

17  
18 Proportion of infants admitted to SCN or NICU.  
19

#### 20 21 22 *Secondary outcomes:*

- 23  
24  
25  
26  
27 a) Proportion of infants receiving exclusive breast milk at three months of age ;  
28  
29 b) Gestational age at birth;  
30  
31 c) Proportion of infants receiving exclusive breast milk during initial hospital stay;  
32  
33 d) Cost of the intervention to hospitals and to women and cost effectiveness against  
34  
35 breastfeeding outcomes;  
36  
37 e) Women's views and experiences;  
38  
39 f) Fetal wellbeing associated with expressing (assessed by CTG at initial then subsequent  
40  
41 opportunistic CTG episodes); antenatal expression episodes, timing and volumes collected  
42  
43 (intervention group only); time to lactogenesis II.  
44  
45  
46  
47  
48

#### 49 50 51 *Potential explanatory variables:*

- 52  
53 g) Reasons for SCN/NICU admissions;  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 h) Hypoglycaemia treatments in maternity or SCN/NICU including glucose gel, IV glucose,  
4  
5 glucagon, hydrocortisone;  
6  
7  
8 i) Length of time until three consecutive infant TBG levels  $\geq 2.6$  mmol/L;  
9  
10  
11 j) Maternal blood glucose levels following first three expressing episodes;  
12  
13 k) Maternal morbidity that could be related to expressing e.g. premature labour.  
14  
15

## 17 **Data collection**

### 18 Maternal and infant

19  
20 *Demographic data* (including age, education, marital status, ethnic background, smoking) will be  
21  
22 collected by questionnaire at recruitment, prior to randomisation.  
23  
24  
25  
26  
27

28  
29 *Obstetric/neonatal medical outcomes* will be abstracted from the medical record following the  
30  
31 birth by researchers blinded to group allocation.  
32  
33  
34

35  
36 *Other outcome data* will be collected by telephone administered questionnaire at 1-2 and 12  
37  
38 weeks postpartum. Women in the intervention arm will complete a diary of their expressing  
39  
40 activity.  
41  
42  
43  
44

### 45 Economic evaluation

46  
47 Resource use data will be collected from the medical record following birth and from women's  
48  
49 self-reported use of health care and other resources in the 12 weeks after the birth. Costs  
50  
51 included in the economic evaluation are those relating to care provided by the hospital (including  
52  
53 admission to SCN/NICU) and women's (infants') use of health care and other societal resources  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 over the period of the evaluation. Measured resource use will be valued using existing unit cost  
4 estimates (e.g., Diagnosis Related Groups cost weights for hospital admissions for mother and  
5 infant<sup>48</sup> and Medicare fee schedules for any attendances at the women's local doctor).<sup>49</sup> As the  
6 primary outcome measure is itself a resource use item, economic evaluation will be expressed as  
7 cost-effectiveness analysis against exclusive breastfeeding at three months.  
8  
9  
10  
11  
12  
13

14  
15  
16  
17 **Blinding:** The nature of the trial necessitates non-blinding of participants assigned to the  
18 intervention group, so that staff know to look for expressed breast milk in the freezer if it is  
19 available and required, and at most sites both the intervention and control groups need to be non-  
20 blinded to ensure that point of care TBGs are performed rather than BSLs, as most sites do BSLs  
21 unless indicated (rather than the TBGs required by this trial). Staff at sites that routinely  
22 undertake TBGs for all infants of women with diabetes in pregnancy will be blinded to women in  
23 the control group. Abstraction of medical record data will be undertaken blinded to group  
24 allocation; data will be presented to the data monitoring committee for the interim analysis in  
25 unlabelled study groups; and the research team will remain blinded to group allocation at all  
26 stages prior to final data analysis.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 **Data analysis**

44  
45 Data will be collected to meet the CONSORT guidelines for reporting of randomised trials,<sup>50</sup>  
46 including data on eligible non-participants. The first stage of analysis will check the  
47 comparability of participants allocated to the two groups. The intervention group will be  
48 compared with the standard care group by intention to treat analysis. The primary outcome  
49 measure will be compared using chi-square tests and odds ratios. Comparison of means will be  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 undertaken for continuous variables using t-tests where data are normally distributed or Mann-  
4  
5 Whitney U tests will compare medians otherwise. Ranked or Likert-type scales will be analysed  
6  
7 using cumulative odds ratios. Where there are differences in baseline characteristics of the  
8  
9 women in the two groups which might be associated with outcomes, an additional multivariate  
10  
11 analysis will be carried out. Duration of breastfeeding will be compared using Kaplan-Meier  
12  
13 statistics. Content analysis will be used to summarise open-ended comments.<sup>51</sup>  
14  
15  
16  
17  
18  
19

20 Research Ethics approval will be sought from La Trobe University and all participating hospitals.  
21  
22  
23

24 **Data and Safety Monitoring Committees:** A Data Monitoring Committee including a  
25  
26 statistician, a midwife and an obstetrician (experienced in conducting RCTs) will undertake an  
27  
28 interim analysis after half the women have given birth. A Safety Committee including a  
29  
30 neonatologist, a midwife and an obstetrician (all experienced clinicians and researchers) will  
31  
32 review reports of any adverse events, e.g. an excess of any of the predefined adverse events for  
33  
34 women or infants, blinded to group allocation (see Supplementary file 2 for list of events). Terms  
35  
36 of reference for each of these committees will guide frequency of reviews and the conditions  
37  
38 under which either committee would advise the research team that enrolment to the trial should  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## DISCUSSION

This will be the first study to provide rigorous evidence regarding the practice of antenatal expression of colostrum in late pregnancy for women with diabetes in pregnancy. It will explore the safety and efficacy for mother, fetus and infant.

1  
2  
3  
4  
5  
6 There remains widespread national and international interest in the outcomes of this trial, and the  
7  
8 controversy can be seen in a recent review which concluded antenatal expressing should be  
9  
10 encouraged: “Although Forster et al.<sup>43</sup> have argued the teaching of [antenatal expressing] should  
11  
12 cease until the practice is proven to be safe and effective ... an ethical dilemma now exists ... as  
13  
14 to whether the benefits of early colostrum feedings in at-risk babies outweighs the unproven side  
15  
16 effect of premature labour.<sup>52</sup> In the absence of evidence, the clear benefits of early feedings of  
17  
18 colostrum should outweigh the unsupported risks of ceasing [antenatal expressing] education.”<sup>53</sup>  
19  
20  
21  
22  
23  
24  
25

## 26 TRIAL STATUS

27  
28  
29 Approval has been granted from the following Human Research Ethics Committees (reference  
30  
31 number in brackets): Royal Women’s Hospital (11/07); Mercy Hospital for Women (11/06 ); La  
32  
33 Trobe University (11-004); Monash Medical Centre (12181-B); Barwon Health (13/06);  
34  
35 Peninsula Health (14/PH/21).  
36  
37  
38  
39  
40  
41

42 Recruitment commenced at Royal Women’s Hospital in June 2011, followed by Mercy Hospital  
43  
44 for Women in July 2011. In May 2012, due to a) the slow recruitment rate resulting from low  
45  
46 numbers of eligible women, and b) external expert advice to include women with diabetes in  
47  
48 pregnancy who did *not* require insulin, thereby increasing the trial’s external validity, it was  
49  
50 agreed to amend our inclusion criteria to include *all* women with diabetes in pregnancy (not just  
51  
52 those requiring insulin) and to identify and recruit further trial sites. Monash Medical Centre  
53  
54 commenced in October 2012 and Barwon Health (Geelong Hospital) in April 2013. The last site,  
55  
56  
57  
58  
59  
60

1  
2  
3 Frankston Hospital, had ethics approval from Peninsula Health in July 2014 and recruitment will  
4  
5 commence soon.  
6  
7  
8  
9  
10

11  
12  
13 In the original protocol women who had a history of spontaneous preterm birth or who had  
14  
15 threatened preterm birth in the current pregnancy were excluded, however following the Safety  
16  
17 Committee review of the first 100 births, which found no evidence of contractions following  
18  
19 expressing, and because no woman is randomised prior to 36 weeks gestation, this exclusion  
20  
21 criterion was removed.  
22  
23  
24  
25  
26

### 27 **Monitoring CTGs**

28  
29 The CTGS for all of the first 100 women who have given birth (pre-randomisation, during and  
30  
31 post-expressing) have been assessed by investigator SPW, with no sign of fetal compromise or  
32  
33 increase in contractions as a result of expressing.  
34  
35  
36  
37  
38

### 39 **Sub-studies**

- 40  
41  
42 1. *Onset of lactation.* In order to determine if the onset of lactation is delayed in women  
43  
44 with diabetes, we are recruiting a comparison group of 200 women without diabetes.  
45  
46 Women are being recruited in the postnatal wards at the Royal Women's Hospital in  
47  
48 2014, and followed by telephone at 1 to 2 weeks postpartum, using identical questions to  
49  
50 the DAME interview.  
51  
52  
53 2. *Antenatal colostrum.* We plan to conduct a biochemical analysis of some excess samples  
54  
55 of antenatal colostrum that infants have not required.  
56  
57  
58  
59  
60

## ACKNOWLEDGEMENTS

We are grateful to all the trial sites for their support of the DAME trial. We also thank the women and their babies participating in this trial.

## COMPETING INTERESTS

None.

## FUNDING

This trial is funded by a project grant from the National Health and Medical Council of Australia (no. 1005345). We have also received equipment grants from the National Health and Medical Council of Australia.

## AUTHORS' CONTRIBUTIONS

Authors: Della A Forster (DAF), Susan Jacobs (SJ), Lisa H Amir (LHA), Peter Davis (PD), Susan P Walker (SPW), Kerri McEgan (KMc), Gillian Opie (GO), Susan M Donath (SMD), Anita M Moorhead (AMM), Rachael Ford (RF), Catharine McNamara (CMc), Amanda Aylward(AA), Lisa Gold (LG)

DAF, AMM, and KMc conceptualised the study, and SJ, LHA, PD, SPW, GO, SMD, RF, CMc, AA and LG contributed to study design. DAF, LHA, AMM, KMc drafted protocol and all

1  
2  
3 authors contributed to protocol revision and application of grant. DAF, LHA, AMM developed  
4 data collection tools and all authors contributed to refinement, piloting and completion of tools.  
5  
6  
7  
8 AMM, KMc, LHA, GO, SJ, and DAF piloted and refined the intervention. AMM, DAF, AA, and  
9  
10 CMc developed the recruitment processes. DAF, AMM, and LHA developed the data collection  
11  
12 process. DAF and LHA drafted the trial protocol manuscript, and all authors read and  
13  
14 contributed to drafts, and read and approved final manuscript.  
15  
16  
17  
18

## 19 REFERENCES

- 21 1 Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in  
22 Australia in the new millennium: measuring health loss from diseases, injuries and risk factors.  
23 *Med J Aust* 2008;188:36-40.
- 24 2 American Diabetes Association. Diagnosis and classification of diabetes mellitus.  
25 *Diabetes Care* 2010;33 Suppl 1:S62-9.
- 26 3 Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a  
27 history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin*  
28 *Endocrinol Metab* 2008;93:4774-9.
- 29 4 Australian Institute of Health and Welfare. Diabetes prevalence in Australia: an  
30 assessment of national data sources. Canberra; 2009.
- 31 5 Mitanchez D, Burguet A, Simeoni U. Infants born to mothers with gestational diabetes  
32 mellitus: mild neonatal effects, a long-term threat to global health. *J Pediatr* 2014;164:445-50.
- 33 6 Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for  
34 mild gestational diabetes. *N Engl J Med* 2009;361:1339-48.
- 35 7 Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious  
36 adverse pregnancy outcome in 933 women with type 1 diabetes. *Diabetes Care* 2009;32:1046-8.
- 37 8 Garcia-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin  
38 requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of  
39 direction. *Diabetologia* 2010;53:446-51.
- 40 9 HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia  
41 and adverse pregnancy outcomes. *N Engl J Med* 2008;358:1991-2002.
- 42 10 Mitanchez D. Foetal and neonatal complications in gestational diabetes: perinatal  
43 mortality, congenital malformations, macrosomia, shoulder dystocia, birth injuries, neonatal  
44 complications. *Diabetes Metab* 2010;36:617-27.
- 45 11 Cardwell CR, Stene LC, Ludvigsson J, et al. Breast-feeding and childhood-onset type 1  
46 diabetes: A pooled analysis of individual participant data from 43 observational studies. *Diabetes*  
47 *Care* 2012;35:2215-25.
- 48 12 Patelarou E, Girvalaki C, Brokalaki H, Patelarou A, Androulaki Z, Vardavas C. Current  
49 evidence on the associations of breastfeeding, infant formula, and cow's milk introduction with  
50 type 1 diabetes mellitus: a systematic review. *Nutr Rev* 2012;70:509-19.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 13 Ip S, Chung M, Raman G, et al. Breastfeeding and Maternal and Infant Health Outcomes in Developed Countries. Rockville, MD: Agency for Healthcare Research and Quality; 2007 April 2007.
- 14 Webster J, Moore K, McMullan A. Breastfeeding outcomes for women with insulin dependent diabetes. *J Hum Lact* 1995;11:195-200.
- 15 Hummel S, Winkler C, Schoen S, et al. Breastfeeding habits in families with Type 1 diabetes. *Diabet Med* 2007;24:671-6.
- 16 Schoen S, Sichert-Hellert W, Hummel S, Ziegler AG, Kersting M. Breastfeeding duration in families with type 1 diabetes compared to non-affected families: results from BABYDIAB and DONALD studies in Germany. *Breastfeed Med* 2008;3:171-75.
- 17 Finkelstein SA, Keely E, Feig DS, Tu X, Yasseen AS, 3rd, Walker M. Breastfeeding in women with diabetes: lower rates despite greater rewards. A population-based study. *Diabet Med* 2013.
- 18 Stage E, Norgard H, Damm P, Mathiesen E. Long-term breast-feeding in women with type 1 diabetes. *Diabetes Care* 2006;29:771-4.
- 19 Kulski JK, Smith M, Hartmann PE. Perinatal concentrations of progesterone, lactose and alpha-lactalbumin in the mammary secretion of women. *J Endocrinol* 1977;74:509-10.
- 20 Murtaugh MA, Ferris AM, Capacchione CM, Reece EA. Energy intake and glycemia in lactating women with type 1 diabetes. *J Am Diet Assoc* 1998;98:642-8.
- 21 Arthur PG, Kent JC, Hartmann PE. Metabolites of lactose synthesis in milk from diabetic and nondiabetic women during lactogenesis II. *J Pediatr Gastroenterol Nutr* 1994;19:100-08.
- 22 Bitman J, Hamosh M, Hamosh P, et al. Milk composition and volume during the onset of lactation in a diabetic mother. *Am J Clin Nutr* 1989;50:1364-69.
- 23 Miyake A, Tahara M, Koike K, Tanizawa O. Decrease in neonatal suckled milk volume in diabetic women. *Eur J Obstet Gynecol Reprod Biol* 1989;33:49-53.
- 24 Neubauer SH, Ferris AM, Chase CG, et al. Delayed lactogenesis in women with insulin-dependent diabetes mellitus. *Am J Clin Nutr* 1993;58:54-60.
- 25 Nommsen-Rivers LA, Dolan LM, Huang B. Timing of stage II lactogenesis is predicted by antenatal metabolic health in a cohort of primiparas. *Breastfeed Med* 2012;7:43-9.
- 26 Hawkins JS, Casey BM. Labor and delivery management for women with diabetes. *Obstet Gynecol Clin N Am* 2007;34:323-34.
- 27 Beucher G, Viaris de Lesegno B, Dreyfus M. Maternal outcome of gestational diabetes mellitus. *Diabetes Metab* 2010;36:522-37.
- 28 Amir LH, Donath S. A systematic review of maternal obesity and breastfeeding intention, initiation and duration. *BMC Pregnancy Childbirth* 2007;7:9.
- 29 Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. *Diabetes Care* 2006;29:1105-07.
- 30 Remsberg KE, McKeown RE, McFarland KF, Irwin LS. Diabetes in pregnancy and cesarean delivery. *Diabetes Care* 1999;22:1561-7.
- 31 Simmons D, Conroy C, Thompson CF. In-hospital breast feeding rates among women with gestational diabetes and pregestational Type 2 diabetes in South Auckland. *Diabetic Med* 2005;22:177-81.
- 32 Renfrew M, Craig D, Dyson L, et al. Breastfeeding promotion for infants in neonatal units: a systematic review and economic analysis. *Health Technol Assess* 2009;13:1-146.

- 1  
2  
3 33 Cox SG. Expressing and storing colostrum antenatally for use in the newborn period.  
4 *Breastfeed Rev* 2006;14:11-6.  
5  
6 34 Rietveld C. Antenatal colostrum harvesting for pregnant women with diabetes mellitus  
7 (DM) (Poster). Midwifery Conference. New Zealand, 2011.  
8 35 Chapman T, Pincombe J, Harris M, Fereday J. Antenatal breast expression: exploration  
9 and extent of teaching practices amongst International Board Certified Lactation Consultant  
10 midwives across Australia. *Women Birth* 2013;26:41-8.  
11 36 Brisbane JM, Giglia RC. Experiences of expressing and storing colostrum antenatally: A  
12 qualitative study of mothers in regional Western Australia. *J Child Health Care* Published online  
13 first: 23 Oct 2013; doi 10.1177/1367493513503586.  
14 37 Tozier PK. Colostrum versus formula supplementation for glucose stabilization in  
15 newborns of diabetic mothers. *JOGGN* 2013;42:619-26.  
16 38 East CE, Dolan WJ, Forster DA. Antenatal breast milk expression by women with  
17 diabetes for improving infant outcomes. *Cochrane Database Syst Rev* 2014;7:CD010408.  
18 39 Cairns and Hinterland Health Service District. Antenatal expression of colostrum  
19 procedure: Queensland Government; 2008.  
20 40 Logan Hospital, Women's and Children's Health Service. Breastfeeding Information for  
21 Pregnant Women with Diabetes. 2009.  
22 41 West D, Marasco L. Getting your milk supply off to a good start. The Breastfeeding  
23 Mother's Guide to Making More Milk. New York: McGraw-Hill, 2009;57-67.  
24 42 Soltani H, Scott AM. Antenatal breast expression in women with diabetes: outcomes  
25 from a retrospective cohort study. *Int Breastfeed J* 2012;7:18.  
26 43 Forster DA, McEgan K, Ford R, et al. Diabetes and antenatal milk expressing: a pilot  
27 project to inform the development of a randomised controlled trial. *Midwifery* 2011;27:209-14.  
28 44 Forster DA, Amir LH, Moorhead A, et al. Is *not* testing a major change in clinical  
29 practice an ethical dilemma? (Letter). *Midwifery* 2011;27:e301-2.  
30 45 Lawrence RA, Lawrence RM. Diabetes mellitus. Breastfeeding: A Guide For The  
31 Medical Profession. 5th ed. St Louis: Mosby, 1999;515-21.  
32 46 Ho HT, Yeung WK, Young BW. Evaluation of "point of care" devices in the  
33 measurement of low blood glucose in neonatal practice. *Arch Dis Child Fetal Neonatal Ed*  
34 2004;89:F356-9.  
35 47 Bonacruz GL, Arnold JD, Leslie GI, Wyndham L, Koumantakis G. Survey of the  
36 definition and screening of neonatal hypoglycaemia in Australia. *J Paediatr Child Health*  
37 1996;32:299-301.  
38 48 Australian Government Department of Health and Ageing. National Hospital Cost Data  
39 Collection, Cost Weights for AR-DRG version 6.0x, Round 14 (2009-10). Canberra; 2012.  
40 49 Australian Government Department of Health and Ageing. Medical Benefits Schedule  
41 Book. Canberra; 2011.  
42 50 Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for  
43 reporting parallel group randomised trials. *PLoS Med* 2010;7:e1000251.  
44 51 Ezzy D. Coding data and interpreting text: methods of analysis. *Qualitative Analysis:  
45 Practice and Innovation*. Sydney: Allen & Unwin, 2002;81-110.  
46 52 Cox S. An ethical dilemma: should recommending antenatal expressing and storing of  
47 colostrum continue? *Breastfeed Rev* 2010;18:5-7.  
48 53 Chapman T, Pincombe J, Harris M. Antenatal breast expression: a critical review of the  
49 literature. *Midwifery* 2013;29:203-10.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure

Figure 1: Schedule of enrolment, intervention, and assessments for the DAME (Diabetes and Antenatal Expressing) trial

### Supplementary files

Supplementary file 1: Instructions for hand expressing and storage of colostrum (early breast milk) for the Diabetes & Antenatal Milk Expressing (DAME) trial

Supplementary file 2: Safety committee terms of reference

For peer review only



# Safety and efficacy of antenatal milk expressing for women with diabetes in pregnancy: protocol for a randomised controlled trial

Della A Forster<sup>1,2\*</sup>, Susan Jacobs<sup>2,3,4</sup>, Lisa H Amir<sup>1</sup>, Peter Davis<sup>2</sup>, Susan P. Walker<sup>4,5</sup>, Kerri McEgan<sup>5</sup>, Gillian Opie<sup>4,5</sup>, Susan M Donath<sup>6</sup>, Anita M. Moorhead<sup>1,2</sup>, Rachael Ford<sup>1,2</sup>, Catharine McNamara<sup>5</sup>, Amanda Aylward<sup>2</sup>, Lisa Gold<sup>7</sup>

## Author affiliations

<sup>1</sup>Judith Lumley Centre (formerly Mother & Child Health Research), La Trobe University, 215 Franklin Street, Melbourne, Victoria 3000, Australia

<sup>2</sup>Royal Women's Hospital, 20 Flemington Rd, Parkville, Victoria 3052, Australia

<sup>3</sup>Clinical Sciences, Murdoch Childrens Research Institute, PO Box 911, Parkville Victoria 3052, Australia

<sup>4</sup>Department of Obstetrics and Gynaecology, University of Melbourne, Victoria 3010, Australia

<sup>5</sup>Mercy Hospital for Women, 163 Studley Road, Heidelberg, Victoria 3084, Australia

<sup>6</sup>Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research Institute, PO Box 911, Parkville Victoria 3052, Australia

<sup>7</sup>Deakin Health Economics, Deakin University, Burwood, Victoria 3125, Australia

## \*Corresponding author:

Prof Della Forster  
Judith Lumley Centre  
La Trobe University  
Level 3  
215 Franklin St  
Melbourne VIC 3000  
AUSTRALIA

Word count, excluding title page and abstract: 5490

References: 52

Figures: 1

Tables 1

## ABSTRACT

### Introduction

Many maternity providers recommend that women with diabetes in pregnancy express and store breast milk in late pregnancy so breast milk is available after birth, given 1) infants of these women are at increased risk of hypoglycaemia in the first 24 hours of life; and 2) the delay in lactogenesis II compared to women without diabetes that increases their infant's risk of receiving infant formula.

The Diabetes and Antenatal Milk Expressing (DAME) trial will establish whether advising women with diabetes in pregnancy (pre-existing or gestational) to express breast milk from 36 weeks gestation increases the proportion of infants who require admission to special or neonatal intensive care units (SCN/NICU) compared with infants of women receiving standard care.

Secondary outcomes include birth gestation, breastfeeding outcomes and economic impact.

### Methods and analysis

Women will be recruited from 34 weeks gestation to a multi-centre, two arm, unblinded randomised controlled trial. The intervention commences at 36 weeks. Randomisation will be stratified by site, parity and diabetes type. Women allocated to the intervention will be taught expressing and encouraged to hand express twice daily for ten minutes and keep an expressing diary. The sample size of 658 (329 per group) will detect a 10% difference in proportion of babies admitted to SCN/NICU (85% power, alpha 0.05). Data are collected at recruitment (structured questionnaire), after birth (abstracted from medical record blinded to group), and 2 and 12 weeks postpartum (telephone interview). *Data analysis*: the intervention group will be

1  
2  
3 compared with the standard care group by intention to treat analysis, and the primary outcome  
4  
5 compared using chi-square and odds ratios.  
6  
7  
8  
9

### 10 **Ethics and dissemination**

11  
12 Research ethics approval will be obtained from participating sites. Results will be published in  
13  
14 peer reviewed journals and presented to clinicians, policy makers and study participants.  
15  
16  
17

18  
19  
20 **Trial Registration:** Australian Controlled Trials Register ACTRN12611000217909  
21  
22  
23

### 24 **Keywords**

25  
26 breast milk, breastmilk, maternal diabetes, gestational diabetes, breastfeeding, randomised  
27  
28 controlled trial (RCT), antenatal expressing, hypoglycaemia, infant, newborn  
29

### 30 **Strengths and limitations of this study**

31  
32 This will be the first study to provide rigorous evidence regarding the practice of antenatal  
33  
34 expression of colostrum in late pregnancy for women with diabetes in pregnancy. It will explore  
35  
36 the safety and efficacy for mother, fetus and infant. The conclusions about antenatal expressing  
37  
38 will be restricted to women with diabetes in pregnancy, but if this practice is found to be safe and  
39  
40 effective for this high risk group, the conclusions are likely to be applicable to other women as  
41  
42 well.  
43  
44  
45  
46  
47  
48

## 49 **BACKGROUND**

50  
51  
52 Diabetes is the second highest contributor to loss of health in Australia.<sup>1</sup> Type 2 diabetes and  
53  
54 gestational diabetes (GDM) are increasing globally.<sup>2</sup> GDM occurs on average in 7% of  
55  
56 pregnancies (range 1 to 14% depending on the population characteristics and diagnostic tests  
57  
58  
59  
60

1  
2  
3 used),<sup>2</sup> and is the strongest single population predictor of type 2 diabetes.<sup>3</sup> An additional 1% of  
4  
5 females aged below 44 years have pre-existing diabetes (type 1 or 2),<sup>4</sup> with type 2 diabetes  
6  
7 increasing in women of childbearing age.<sup>5</sup> Since 2009, women found to have glucose intolerance  
8  
9 at the first pregnancy visit are diagnosed as having type 2 diabetes (not GDM).<sup>2</sup> In Victoria in  
10  
11 2008, 6.1% of all women giving birth had diabetes in pregnancy (personal communication, A  
12  
13 Cooper, Perinatal Data Collection Unit). At the planned original study sites, the Royal Women's  
14  
15 Hospital (RWH) and Mercy Hospital for Women (MHW), 7.7% (495/6443) and 10.3%  
16  
17 (690/5748) of women respectively giving birth in 2009 had diabetes in pregnancy.  
18  
19  
20  
21  
22  
23

24 Pregnancies affected by diabetes have increased risk of perinatal complications, including  
25  
26 increased perinatal mortality for infants of women with type 1 diabetes.<sup>6-8</sup> In gestational diabetes,  
27  
28 poorer glycaemic control is also associated with adverse infant outcomes.<sup>9</sup>  
29  
30  
31  
32  
33

34 Infants of women with diabetes in pregnancy are at increased risk of hypoglycaemia (secondary  
35  
36 to hyperinsulinism) and other morbidities in the early neonatal period (e.g. macrosomia,  
37  
38 respiratory distress syndrome, prematurity, congenital anomalies, polycythaemia, jaundice).<sup>5, 10</sup>  
39  
40 They are more likely to themselves develop diabetes, and have an increased risk of obesity later  
41  
42 in life.<sup>5</sup>  
43  
44  
45  
46  
47  
48

49 A strategy to decrease the risk of these infants developing diabetes or impaired glucose tolerance  
50  
51 later in life would be one way of interrupting the cycle of diabetes. One such strategy is to  
52  
53 increase the rate of exclusive breastfeeding from birth in these infants, given that early exposure  
54  
55 to cow's milk protein increases the incidence of both type 1 (juvenile onset) and later onset type  
56  
57  
58  
59  
60

1  
2  
3 2 diabetes.<sup>11-13</sup> However, infants of women with diabetes are at high risk of not being exclusively  
4 breastfed for a number of reasons. Studies have found generally that women with diabetes are  
5  
6 less likely to breastfeed than other women, and likely to breastfeed for a shorter duration,<sup>14-17</sup>  
7  
8 although one study has found that where breastfeeding is encouraged and supported, women with  
9  
10 diabetes can be just as successful as women without diabetes.<sup>18</sup>  
11  
12  
13

14  
15  
16  
17 Lactogenesis II, the onset of copious milk production, usually occurs 30 to 40 hours after birth.<sup>19</sup>  
18  
19 Women with diabetes experience up to a 24 hour delay in lactogenesis II compared to women  
20  
21 without diabetes,<sup>20-24</sup> as do women with glucose intolerance, increasing their infants' risk of  
22  
23 receiving infant formula.<sup>25</sup> Women with diabetes are also at risk of other co-morbidities, most  
24  
25 commonly obesity.<sup>26, 27</sup> In turn, obese women<sup>28</sup> and obese women with diabetes<sup>29</sup> are less likely  
26  
27 to successfully breastfeed. Separation of mother and infant following caesarean birth (also more  
28  
29 likely in women with diabetes in pregnancy<sup>27, 30</sup>) and/or admission to special and neonatal  
30  
31 intensive care units (SCN/NICU), further decreases the likelihood of establishing  
32  
33 breastfeeding.<sup>31, 32</sup>  
34  
35  
36  
37  
38  
39  
40

41 Since infants of women with diabetes are at increased risk of hypoglycaemia<sup>10</sup> they require blood  
42  
43 glucose monitoring and are often admitted to the SCN. If infants are hypoglycaemic and their  
44  
45 mother is unable to provide a sufficient volume of expressed breast milk in addition to  
46  
47 breastfeeding, they may receive supplementation with infant formula or intravenous glucose.

48  
49 This has led to a practice whereby some women with diabetes in pregnancy are being advised to  
50  
51 express breast milk before their infant's birth.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Current practice

Increasing numbers of maternity providers are encouraging pregnant women with diabetes to express and store breast milk (colostrum) in the last weeks before their expected delivery date,<sup>33-38</sup> so that breast milk is available in the postpartum period, thereby possibly avoiding infant formula if neonatal hypoglycaemia needs management with supplementary formula feeding. Some organisations have implemented guidelines for antenatal expressing of colostrum,<sup>39, 40</sup> and in a recent book for consumers, there is a section entitled “Getting a head start: expressing milk before your baby is born”.<sup>41, p. 57</sup> This practice pre-supposes that establishing a supply of colostrum pre-birth might ameliorate: i) the number of infants of women with diabetes who receive infant formula or intravenous glucose if supplementary feeding is required to treat neonatal hypoglycaemia (stored colostrum could be used); ii) the delay in lactogenesis II in women with diabetes; and iii) the number of infants of women with diabetes admitted to the SCN. These recommendations for practice have not been investigated and are therefore theoretical, and there is very limited evidence regarding the safety or efficacy of encouraging antenatal expressing of breast milk.

## The evidence

A retrospective cohort study from the UK included 94 women, and found that infants of women with diabetes who expressed were born one week earlier on average (37.1 weeks (SD 2.6), compared to 38.2 weeks (SD 2.2),  $p = 0.06$ ), and were more likely to be admitted to the SCN.<sup>42</sup> We conducted a pilot study in 2007 that also provided some evidence, and provided the baseline data to undertake the proposed randomised controlled trial (RCT).<sup>43</sup> We recruited 43 women with diabetes in pregnancy who agreed to undertake antenatal expressing (35% of those eligible

1  
2  
3 agreed to participate when invited) and we conducted a concurrent audit of clinical outcomes in a  
4 group of infants of similar women (with diabetes in pregnancy) to provide 'control' data.  
5  
6

7  
8 Women in the expressing pilot completed a demographic questionnaire, were then taught how to  
9 express colostrum, and encouraged to do so for ten minutes twice daily from 36 weeks gestation.  
10  
11 They were advised on the safe storage of colostrum, which they froze for their baby's use after  
12 birth. Women kept a diary documenting their expressing and completed telephone interviews at 6  
13 and 12 weeks postpartum. We found that 30% of infants in the pilot were admitted to SCN  
14 compared with 17% of 'control' infants, and that reasons for admission to SCN were similar in  
15 the two groups.<sup>43</sup> Intravenous glucose use was 14% for pilot infants and 8% for control infants  
16 (RR 1.77; 95% CI 0.63, 4.96). There was no evidence of any fetal compromise based on  
17 cardiocotographs (CTGs) undertaken after the first expressing episode. Women recorded blood  
18 sugar levels (BSLs) following their first three expressing episodes. Although the median BSLs  
19 were normal and suggested no evidence of hypoglycaemia at a group level, 10% (2/20) of  
20 women had a BSL < 3.5 mmol/L after the first expressing episode, and seven women (27%;  
21 7/29) reported they experienced tightenings or Braxton Hicks contractions as a result of antenatal  
22 expressing, and one ceased the intervention for this reason.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The amount of colostrum women obtained varied according to number of expressions, length of  
44 time between onset of expressing and birth and the time spent expressing, with a median of 14  
45 days expressing and 40 ml (range 5 to 310 ml) obtained. Although some women found  
46 expressing difficult (31%), the intervention was positively received overall, and 95% (38/40) of  
47 women would express antenatally again if proven beneficial. More infants in the pilot received  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 exclusive breast milk during their postpartum hospital stay (37%) compared to the 'control'  
4  
5 group (27%) (RR 1.38; 95% CI 0.82, 2.31).  
6  
7  
8  
9

10 In January 2010, we conducted a telephone survey of 48 tertiary and large metropolitan and  
11 regional maternity hospitals across Australia providing care for 109,465 births per year and  
12 found that 30 of these services (63%; 65,478 births) recommend antenatal milk expressing.<sup>44</sup> Of  
13 these, 21 (70%) recommended antenatal expressing primarily to women with diabetes in  
14 pregnancy (although the practice is also being recommended to women with other high risk  
15 pregnancies), and 11 (37%) had a policy or guideline for antenatal milk expressing. Across the  
16 11 services with a policy or guideline for antenatal milk expressing, the mean gestation  
17 recommended for commencement of expressing was 36 weeks (range 30-37 weeks). Of the 18  
18 services (38%; 43987 births) who *did not* recommend this practice, five (28%) discontinued  
19 antenatal expressing based on the recommendations of our pilot observational study,<sup>43</sup> and await  
20 evidence to inform this practice.<sup>44</sup>  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 A recent Cochrane review identified no RCTs that investigated the practice of expressing and  
40 storing breast milk during pregnancy, and concluded that there is no high level systematic  
41 evidence to inform the safety and efficacy of this practice.<sup>38</sup> Rigorous evidence is urgently  
42 required to inform the clinical practice of antenatal expression of colostrum.<sup>44</sup> This paper  
43 describes the protocol for an adequately powered RCT exploring the practice of advising women  
44 with diabetes in pregnancy to express breast milk from 36 weeks gestation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## 56 METHODS

57  
58  
59  
60



1  
2  
3 A multi-centre, two arm, unblinded RCT design will be used to compare the practice of antenatal  
4 milk expressing with standard care, for women with pre-existing or gestational diabetes. In the  
5 original trial design we included only women with diabetes in pregnancy who required insulin,  
6 choosing this group because they are the women for whom antenatal expressing is most often  
7 suggested, yet are at the highest risk of perinatal complications, particularly if glycaemic control  
8 is poor. This inclusion criterion changed, as detailed below in the sample size section.  
9  
10  
11  
12  
13  
14  
15  
16

## 17 18 **Aims**

### 19 20 *Primary aim:*

21 To establish whether the practice of antenatal expressing of colostrum from 36 weeks gestation,  
22 for women with diabetes in pregnancy, increases the proportion of infants who require admission  
23 to the SCN or NICU compared with the infants of similar women receiving standard care.  
24  
25  
26  
27  
28  
29  
30  
31

### 32 33 *Primary hypothesis:*

34 Infants of women with diabetes in pregnancy who commence antenatal expressing of colostrum  
35 from 36 weeks gestation will be more likely to be admitted to the SCN or NICU during the  
36 primary hospitalisation after birth compared with the infants of women with diabetes in  
37 pregnancy receiving standard care.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 47 *Secondary aims:*

48 To determine whether antenatal expressing of colostrum from 36 weeks gestation for women  
49 with diabetes in pregnancy, compared with similar women receiving standard care:  
50  
51

52 a) *increases* the proportion of infants receiving exclusive breast milk at three months of age (i.e.  
53 is effective in promoting exclusive breastfeeding);  
54  
55  
56  
57  
58  
59  
60

b) *decreases* the mean gestation at birth (i.e. is harmful);

c) *increases* the proportion of infants receiving exclusive breast milk during initial hospital stay (i.e. is effective).

We will also:

d) Test the cost and cost effectiveness of this intervention compared with standard care;

e) Explore the views and experiences of women participating in this trial; and

f) Collect data on other outcomes – e.g. fetal well-being associated with expressing; volumes of antenatal colostrum obtained; time to onset of lactogenesis II (onset of copious milk production).

Table 1 summarises the potential harms and benefits of antenatal expressing of colostrum.

**Table 1: Potential harms and benefits of antenatal breast milk expressing**

Potential harms	Potential benefits
Increased admissions to SCN/NICU (shows increased neonatal morbidity and mother-infant separation)	Increased exclusive breastfeeding during initial hospital stay Increased exclusive breastfeeding at 3 months postpartum Increased duration of any breastfeeding
Decreased mean duration of pregnancy	Improved maternal satisfaction
Increased requirement for IV glucose	Decreased risk of subsequent diabetes for the infant*

### Study sample

All eligible women booking for maternity care at the trial sites during the recruitment period will be offered study participation.

*Inclusion criteria:* Any woman:

(1) with pre-existing or gestational diabetes

(2) between 34 and 36 weeks gestation (but not more than 37 weeks);

(3) with a singleton pregnancy in a cephalic presentation;

1  
2  
3 (4) attending the study sites for pregnancy care as a public patient;  
4  
5

6 (5) planning to breastfeed; and  
7

8 (6) able to speak and read in English.  
9

10 Exclusion criteria: Women with:  
11

12 (1) any history of antepartum haemorrhage, or placenta praevia (even in the absence of any  
13 antenatal bleeding);  
14

15 (2) an unknown or classical caesarean section scar or more than one lower segment caesarean  
16 section scar;  
17

18 (3) any suspicion of fetal compromise including known or suspected intrauterine growth  
19 restriction, documented macrosomia (estimated fetal weight  $\geq$  95<sup>th</sup> percentile) with abdominal  
20 circumference  $>$  97<sup>th</sup> centile, polyhydramnios or any abnormal tests of fetal well-being (whether  
21 clinically, ultrasound or CTG based); or  
22

23 (4) a known fetal anomaly.  
24

25 (5) Hypertension and proteinuria - if any concerns about fetal wellbeing  
26

27 (6) A serious maternal mental health issue, other severe maternal obstetric/medical issue.  
28

29 In some sites there are small proportions of infants who are automatically admitted to the SCN  
30 after birth, e.g. infants of women who have Type 1 or Type 2 diabetes, or women on higher  
31 doses of insulin. In these sites, given the primary outcome is SCN/NICU admission; the women  
32 in those groups will be ineligible for inclusion in the trial.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **Recruitment**

51 Eligible women will be identified and offered participation by a study midwife at 34-36 weeks  
52 gestation, to maximise the opportunity to recruit women. If the woman is interested she will  
53 provide written consent and complete a questionnaire regarding demographic details and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 breastfeeding intentions. Randomisation occurs at 36 weeks gestation, so recruitment and  
4  
5 randomisation will often be a two stage process. Prior to randomisation women will have a  
6  
7 preliminary 20 minute CTG, and if the CTG is assessed as reactive and without significant  
8  
9 uterine activity, the woman will be randomised to one of the two trial arms. Women allocated to  
10  
11 the intervention will be taught hand expressing at that time (detailed more fully below), with a  
12  
13 CTG during this first 10 minute expressing episode and for 20 minutes after. The schedule of  
14  
15 participant enrollment, intervention and assessments is shown in Figure 1.  
16  
17  
18  
19  
20  
21

### 22 **Randomisation procedure**

23  
24 Randomisation is stratified by site, first baby or not, and diabetes type (i.e. pre-existing (Type 1  
25  
26 or Type 2), gestational requiring insulin, or gestational not requiring insulin). A computerised  
27  
28 random number generator was used to select random permuted blocks with at least three  
29  
30 different block sizes. A system designed and administered by the Clinical Epidemiology and  
31  
32 Biostatistics Unit at Murdoch Childrens Research Institute is accessed by the internet to ascertain  
33  
34 women's allocation.  
35  
36  
37  
38  
39  
40

### 41 **The intervention**

42  
43 Women randomised to the intervention will *receive all standard advice and care* (guided by  
44  
45 existing hospital protocols) *as well as* receiving instructions on the intervention. They will be  
46  
47 taught how to hand express colostrum (Supplementary file 1). Women will be encouraged to  
48  
49 express twice daily for *no more* than ten minutes until being admitted to hospital to give birth,  
50  
51 unless any concerns arise which indicate that the intervention should cease (see below).  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Women will be provided with written and verbal instructions on the safe storage and  
4  
5 transportation of colostrum (Supplementary file 1). Expressed colostrum will be labelled with the  
6  
7 woman's hospital medical record number and kept in syringes in her home freezer. Women will  
8  
9 be asked to bring the frozen colostrum in an 'esky' (cold storage box) when they are admitted for  
10  
11 the birth. Women will be provided with all the equipment they require for this intervention:  
12  
13 syringes (2 and 5 ml), small eskies, ice pack and specimen bags, labels with medical record  
14  
15 number, and diaries to document each episode of expressing.  
16  
17  
18  
19  
20  
21

22 A dedicated freezer will be available at each trial site for storage of antenatally expressed frozen  
23  
24 colostrum. Midwifery and neonatal staff will receive education about the trial and be informed as  
25  
26 to where to store the frozen expressed breast milk.  
27  
28  
29

### 30 **Ensuring maternal and fetal well-being**

#### 31 *Surveillance in hospital*

32  
33 Women in the intervention group will undertake an expressing episode under CTG surveillance  
34  
35 at the time they are taught expressing (immediately after randomisation). If a woman requires  
36  
37 further CTG's during their pregnancy care she will be asked to do one of her expressing episodes  
38  
39 during those CTGs, as the uterus may become more sensitive to the resultant oxytocin surge with  
40  
41 advancing gestation. The protocol for subsequent CTGs and expressing will be identical to that  
42  
43 of the initial expressing episode i.e. preliminary CTG, express for ten minutes, then continue the  
44  
45 CTG for 20 minutes post-expression. The CTG must be reactive prior to commencing  
46  
47 expressing. Immediate discontinuation of expressing will occur if there are any signs of fetal  
48  
49 compromise (fetal tachycardia, reduced variability, late decelerations), or if there is excessive  
50  
51 uterine activity (either a hypertonic contraction (one lasting longer than 90 seconds), or  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 tachysystole (> 5 contractions per 10 minute period)). Each participating centre will follow their  
4  
5 existing protocol for management of fetal distress, including availability of acute tocolysis and  
6  
7 on-site obstetric support.  
8  
9

### 10 11 12 *Surveillance at home*

13  
14 Women will be advised of precautions related to expressing in the antenatal period and informed  
15  
16 that if they have concerns regarding any of these issues they should telephone the study midwife,  
17  
18 or the Emergency Department/Birth suite of their relevant hospital after hours. Instructions will  
19  
20 be given regarding the importance of:  
21  
22

- 23 1. Noting normal fetal activity prior to expressing.
- 24 2. Reporting any complications after expressing, such as excessive uterine activity, vaginal  
25  
26 blood loss, decreased fetal movements, or signs of hypoglycaemia.
- 27 3. Measuring BSLs after the first three episodes of expressing, to ensure that the expressing is  
28  
29 not causing hypoglycaemia (which can occur with breastfeeding).<sup>45</sup> A consultant endocrinologist  
30  
31 will advise the research team on maternal diabetes care as needed, and assist with interpretation  
32  
33 of relevant outcomes.  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Standard care**

43  
44 All women with pre-existing or gestational diabetes are seen by a Diabetes Educator for  
45  
46 management of their diabetes. Additionally, all women discuss breastfeeding with midwives  
47  
48 during pregnancy, and at all sites women can ask to see a lactation consultant in the antenatal  
49  
50 period if they wish. No site can participate in the trial if they recommend that women express  
51  
52 colostrum in the antenatal period.  
53  
54  
55  
56  
57  
58  
59  
60

## Management of neonatal hypoglycaemia

The intervention being tested is not aimed at preventing hypoglycaemia, however in practice the aim of many clinicians who advise antenatal milk expressing for this group is to avoid the use of formula for supplementary feeding if/when neonatal hypoglycaemia occurs. Based on our pilot data, approximately half of the admissions to SCN or NICU will be for neonatal hypoglycaemia.<sup>43</sup> We will measure the incidence and duration of neonatal hypoglycaemia; however it is not expected that encouraging women to express prior to birth could of itself prevent neonatal hypoglycaemia.

Existing guidelines for management of newborn infants at risk of hypoglycaemia, including infants of women with diabetes in pregnancy, will be followed. While there may be slight variations in guidelines by trial site, for the purposes of data analysis neonatal hypoglycaemia is defined as a true blood glucose (TBG) < 2.6 mmol/L as measured on a blood gas analyser (or portable point of care TBG analyser) or in the laboratory. Sites whose guidelines for management of newborn infants at risk of hypoglycaemia are too different from this are not eligible to participate in the trial, and site guidelines are reviewed by the trial neonatologist prior to a decision about any site's suitability for inclusion. Although bedside testing with a glucometer is possible (providing BSLs), this method is not accurate at low blood glucose levels, when a TBG is mandatory. Prompt, standardised and accurate blood glucose measurement of TBG is optimal,<sup>46, 47</sup> and in the trial will eliminate measurement bias in either trial arm. A portable point of care TBG analyser will facilitate prompt, accurate TBG measurement at the bedside without separation of mother and baby – crucial in supporting early breastfeeding.

1  
2  
3 Stratification by site ensures that any slight variation in infant glucose management will not  
4 affect trial outcomes. Regardless of group assignment, mothers will breastfeed their infants, and  
5 express their milk postpartum if required. The first response to hypoglycaemia (as per existing  
6 clinical guidelines at the two primary trial sites, RWH and MHW) is a prescribed volume (30-60  
7 ml/kg/day of supplemental feed of expressed breast milk or infant formula, or glucose gel  
8 (0.5mL/kg of 40%) massaged into buccal mucosa. Hypoglycaemia unresponsive to supplemental  
9 feeding triggers admission to SCN/NICU, more frequent, larger supplemental feeds, further  
10 glucose gel or IV glucose therapy, to achieve normal TBGs.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Process evaluation**

26 Adherence to the study protocol and intervention fidelity will be monitored.

- 27  
28  
29 (1) *Measures of intervention exposure:* Women in the intervention group will keep a diary of  
30 antenatal expressing, noting: date and time of day each expressing episode takes place, length of  
31 each expressing episode, and volume of colostrum expressed. Women in the control group will  
32 be asked at the 1 to 2 week interview if they expressed antenatally, to check for any cross-over.  
33  
34 (2) Monthly meetings with all project staff will include discussion of protocol adherence,  
35 measurement and documentation.  
36  
37 (3) Intervention evaluation by participants: The telephone interview at twelve weeks postpartum  
38 will include questions regarding women's views and experiences of being in the trial.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Sample size**

50 Given the aim of antenatal expressing of breast milk is to benefit infants of women with diabetes  
51 in pregnancy, we debated whether our primary outcome should test efficacy or safety. Because  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 our pilot data suggested potential harm, we chose the primary hypothesis to test safety. We are  
4  
5 also powered to test the listed secondary outcomes.  
6  
7

8  
9 *Primary outcome:*

10  
11 As mentioned above, when we designed the trial originally, we included only women with  
12  
13 diabetes in pregnancy who required insulin, and our sample size calculations were based on  
14  
15 estimates of this group. With that population we needed an estimated sample size of 658 women  
16  
17 (329 in each group) based on 80% power (alpha 0.05), and allowing 5% loss to follow up. This  
18  
19 allowed the detection of an increase in the proportion of infants of women (requiring insulin in  
20  
21 pregnancy) who are admitted to SCN or NICU in the primary hospital admission following birth,  
22  
23 from 20% in the control group to 30% in the intervention group. This estimate was derived from  
24  
25 the pilot and audit data presented above.  
26  
27  
28  
29  
30  
31

32  
33 *Secondary outcomes:*

34  
35 This sample size also allows detection of:

- 36  
37 (a) a difference in exclusive breastfeeding at 3 months of 12% (40% in the control group  
38  
39 compared with 52% in the intervention group) (assuming the infants in the intervention achieve  
40  
41 the same rate as the state-wide data and as per our pilot, i.e. 52%) (requires n=254);  
42  
43 (b) a difference in the mean duration of pregnancy (38 weeks in the control group compared with  
44  
45 37 weeks in the intervention group) (requires n=184; means, SDs derived from Soltani study<sup>42</sup>);  
46  
47 and  
48  
49 (c) a difference in exclusive breastfeeding during initial hospital stay of 12% (25% in the control  
50  
51 group compared with 37% in the intervention group).  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Sample size revision May 2012*

Recruitment to the trial as per the original criteria commenced in July 2011. In May 2012 it was agreed to amend our inclusion criteria to include all women with diabetes in pregnancy. This was due to two factors a) the slow recruitment rate due to smaller numbers of eligible women than anticipated, and b) expert advice from outside the research group recommending that the external validity of the trial would be increased if the criteria were broadened to also include women with diabetes in pregnancy who did not require insulin.

The change of inclusion criteria meant that a baseline rate of admission to the SCN or NICU would be 17% rather than 20% as per our original sample size calculations (based on a review of all 2011 outcome data for women with diabetes in pregnancy at the RWH). We undertook various recalculations to address this. Regarding the sample size with the altered baseline:

- to detect 10% absolute difference (as in the original calculation) we would need 289 per group – this would be a decrease in sample size – which none of the team considered optimal;
- to detect a 50% relative increase to 25.7% would need 379 per group, i.e. 758 (100 more than current sample of 658) – again this is not ideal as the study is not funded for this and we did not use this difference in our original calculations;
- or we could maintain current sample size (658) and describe the study power to detect a 10% absolute difference.

The final option was chosen, i.e. we agreed to maintain the current sample size and assume increased power to detect 10% absolute difference. Allowing for 5% loss to follow up, the

1  
2  
3 original sample size of 658 would provide 625 women at primary outcome measurement. This  
4  
5 would detect a change in primary outcome from 17% to 27% with a power of 85%. All the  
6  
7 original secondary outcome comparisons described above will be maintained given the sample  
8  
9 size has not altered.  
10  
11

### 12 13 14 15 **Outcome variables**

#### 16 17 *Primary outcome:*

18  
19 Proportion of infants admitted to SCN or NICU.  
20  
21

#### 22 23 24 *Secondary outcomes:*

- 25  
26
- 27 a) Proportion of infants receiving exclusive breast milk at three months of age ;
  - 28 b) Gestational age at birth;
  - 29 c) Proportion of infants receiving exclusive breast milk during initial hospital stay;
  - 30 d) Cost of the intervention to hospitals and to women and cost effectiveness against
  - 31 breastfeeding outcomes;
  - 32 e) Women's views and experiences;
  - 33 f) Fetal wellbeing associated with expressing (assessed by CTG at initial then subsequent
  - 34 opportunistic CTG episodes); antenatal expression episodes, timing and volumes collected
  - 35 (intervention group only); time to lactogenesis II.
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49

#### 50 51 *Potential explanatory variables:*

- 52  
53 g) Reasons for SCN/NICU admissions;
- 54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 h) Hypoglycaemia treatments in maternity or SCN/NICU including glucose gel, IV glucose,  
4  
5 glucagon, hydrocortisone;  
6  
7  
8 i) Length of time until three consecutive infant TBG levels  $\geq 2.6$  mmol/L;  
9  
10  
11 j) Maternal blood glucose levels following first three expressing episodes;  
12  
13 k) Maternal morbidity that could be related to expressing e.g. premature labour.  
14  
15

## 16 17 **Data collection**

### 18 Maternal and infant

19  
20 *Demographic data* (including age, education, marital status, ethnic background, smoking) will be  
21  
22 collected by questionnaire at recruitment, prior to randomisation.  
23  
24  
25  
26  
27

28  
29 *Obstetric/neonatal medical outcomes* will be abstracted from the medical record following the  
30  
31 birth by researchers blinded to group allocation.  
32  
33  
34  
35

36  
37 *Other outcome data* will be collected by telephone administered questionnaire at 1-2 and 12  
38  
39 weeks postpartum. Women in the intervention arm will complete a diary of their expressing  
40  
41 activity.  
42  
43  
44  
45

### 46 Economic evaluation

47  
48 Resource use data will be collected from the medical record following birth and from women's  
49  
50 self-reported use of health care and other resources in the 12 weeks after the birth. Costs  
51  
52 included in the economic evaluation are those relating to care provided by the hospital (including  
53  
54 admission to SCN/NICU) and women's (infants') use of health care and other societal resources  
55  
56  
57  
58  
59  
60

1  
2  
3 over the period of the evaluation. Measured resource use will be valued using existing unit cost  
4 estimates (e.g., Diagnosis Related Groups cost weights for hospital admissions for mother and  
5 infant<sup>48</sup> and Medicare fee schedules for any attendances at the women's local doctor).<sup>49</sup> As the  
6 primary outcome measure is itself a resource use item, economic evaluation will be expressed as  
7 cost-effectiveness analysis against exclusive breastfeeding at three months.  
8  
9  
10  
11  
12  
13

14  
15  
16  
17 **Blinding:** The nature of the trial necessitates non-blinding of participants assigned to the  
18 intervention group, so that staff know to look for expressed breast milk in the freezer if it is  
19 available and required, and at most sites both the intervention and control groups need to be non-  
20 blinded to ensure that point of care TBGs are performed rather than BSLs, as most sites do BSLs  
21 unless indicated (rather than the TBGs required by this trial). Staff at sites that routinely  
22 undertake TBGs for all infants of women with diabetes in pregnancy will be blinded to women in  
23 the control group. Abstraction of medical record data will be undertaken blinded to group  
24 allocation; data will be presented to the data monitoring committee for the interim analysis in  
25 unlabelled study groups; and the research team will remain blinded to group allocation at all  
26 stages prior to final data analysis.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 **Data analysis**

44  
45 Data will be collected to meet the CONSORT guidelines for reporting of randomised trials,<sup>50</sup>  
46 including data on eligible non-participants. The first stage of analysis will check the  
47 comparability of participants allocated to the two groups. The intervention group will be  
48 compared with the standard care group by intention to treat analysis. The primary outcome  
49 measure will be compared using chi-square tests and odds ratios. Comparison of means will be  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 undertaken for continuous variables using t-tests where data are normally distributed or Mann-  
4  
5 Whitney U tests will compare medians otherwise. Ranked or Likert-type scales will be analysed  
6  
7 using cumulative odds ratios. Where there are differences in baseline characteristics of the  
8  
9 women in the two groups which might be associated with outcomes, an additional multivariate  
10  
11 analysis will be carried out. Duration of breastfeeding will be compared using Kaplan-Meier  
12  
13 statistics. Content analysis will be used to summarise open-ended comments.<sup>51</sup>  
14  
15  
16  
17  
18  
19

20 Research Ethics approval will be sought from La Trobe University and all participating hospitals.  
21  
22  
23

24 **Data and Safety Monitoring Committees:** A Data Monitoring Committee including a  
25  
26 statistician, a midwife and an obstetrician (experienced in conducting RCTs) will undertake an  
27  
28 interim analysis after half the women have given birth. A Safety Committee including a  
29  
30 neonatologist, a midwife and an obstetrician (all experienced clinicians and researchers) will  
31  
32 review reports of any adverse events, e.g. an excess of any of the predefined adverse events for  
33  
34 women or infants, blinded to group allocation (see Supplementary file 2 for list of events). Terms  
35  
36 of reference for each of these committees will guide frequency of reviews and the conditions  
37  
38 under which either committee would advise the research team that enrolment to the trial should  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## DISCUSSION

This will be the first study to provide rigorous evidence regarding the practice of antenatal expression of colostrum in late pregnancy for women with diabetes in pregnancy. It will explore the safety and efficacy for mother, fetus and infant.

1  
2  
3  
4  
5  
6 There remains widespread national and international interest in the outcomes of this trial, and the  
7  
8 controversy can be seen in a recent review which concluded antenatal expressing should be  
9  
10 encouraged: “Although Forster et al.<sup>43</sup> have argued the teaching of [antenatal expressing] should  
11  
12 cease until the practice is proven to be safe and effective ... an ethical dilemma now exists ... as  
13  
14 to whether the benefits of early colostrum feedings in at-risk babies outweighs the unproven side  
15  
16 effect of premature labour.<sup>52</sup> In the absence of evidence, the clear benefits of early feedings of  
17  
18 colostrum should outweigh the unsupported risks of ceasing [antenatal expressing] education.”<sup>53</sup>  
19  
20  
21  
22  
23  
24  
25

## 26 TRIAL STATUS

27  
28  
29 Approval has been granted from the following Human Research Ethics Committees (reference  
30  
31 number in brackets): Royal Women’s Hospital (11/07); Mercy Hospital for Women (11/06 ); La  
32  
33 Trobe University (11-004); Monash Medical Centre (12181-B); Barwon Health (13/06);  
34  
35 Peninsula Health (14/PH/21).  
36  
37  
38  
39  
40  
41

42 Recruitment commenced at Royal Women’s Hospital in June 2011, followed by Mercy Hospital  
43  
44 for Women in July 2011. In May 2012, due to a) the slow recruitment rate resulting from low  
45  
46 numbers of eligible women, and b) external expert advice to include women with diabetes in  
47  
48 pregnancy who did *not* require insulin, thereby increasing the trial’s external validity, it was  
49  
50 agreed to amend our inclusion criteria to include *all* women with diabetes in pregnancy (not just  
51  
52 those requiring insulin) and to identify and recruit further trial sites. Monash Medical Centre  
53  
54 commenced in October 2012 and Barwon Health (Geelong Hospital) in April 2013. The last site,  
55  
56  
57  
58  
59  
60

1  
2  
3 Frankston Hospital, had ethics approval from Peninsula Health in July 2014 and recruitment will  
4  
5 commence soon.  
6  
7  
8  
9

10  
11  
12  
13 In the original protocol women who had a history of spontaneous preterm birth or who had  
14  
15 threatened preterm birth in the current pregnancy were excluded, however following the Safety  
16  
17 Committee review of the first 100 births, which found no evidence of contractions following  
18  
19 expressing, and because no woman is randomised prior to 36 weeks gestation, this exclusion  
20  
21 criterion was removed.  
22  
23  
24  
25  
26

### 27 **Monitoring CTGs**

28  
29 The CTGS for all of the first 100 women who have given birth (pre-randomisation, during and  
30  
31 post-expressing) have been assessed by investigator SPW, with no sign of fetal compromise or  
32  
33 increase in contractions as a result of expressing.  
34  
35  
36  
37  
38

### 39 **Sub-studies**

- 40  
41  
42 1. *Onset of lactation.* In order to determine if the onset of lactation is delayed in women  
43  
44 with diabetes, we are recruiting a comparison group of 200 women without diabetes.  
45  
46 Women are being recruited in the postnatal wards at the Royal Women's Hospital in  
47  
48 2014, and followed by telephone at 1 to 2 weeks postpartum, using identical questions to  
49  
50 the DAME interview.  
51  
52  
53 2. *Antenatal colostrum.* We plan to conduct a biochemical analysis of some excess samples  
54  
55 of antenatal colostrum that infants have not required.  
56  
57  
58  
59  
60



## ACKNOWLEDGEMENTS

We are grateful to all the trial sites for their support of the DAME trial. We also thank the women and their babies participating in this trial.

## COMPETING INTERESTS

None.

## FUNDING

This trial is funded by a project grant from the National Health and Medical Council of Australia (no. 1005345). We have also received equipment grants from the National Health and Medical Council of Australia.

## AUTHORS' CONTRIBUTIONS

Authors: Della A Forster (DAF), Susan Jacobs (SJ), Lisa H Amir (LHA), Peter Davis (PD), Susan P Walker (SPW), Kerri McEgan (KMc), Gillian Opie (GO), Susan M Donath (SMD), Anita M Moorhead (AMM), Rachael Ford (RF), Catharine McNamara (CMc), Amanda Aylward(AA), Lisa Gold (LG)

DAF, AMM, and KMc conceptualised the study, and SJ, LHA, PD, SPW, GO, SMD, RF, CMc, AA and LG contributed to study design. DAF, LHA, AMM, KMc drafted protocol and all

1  
2  
3 authors contributed to protocol revision and application of grant. DAF, LHA, AMM developed  
4 data collection tools and all authors contributed to refinement, piloting and completion of tools.  
5  
6  
7  
8 AMM, KMc, LHA, GO, SJ, and DAF piloted and refined the intervention. AMM, DAF, AA, and  
9  
10 CMc developed the recruitment processes. DAF, AMM, and LHA developed the data collection  
11  
12 process. DAF and LHA drafted the trial protocol manuscript, and all authors read and  
13  
14 contributed to drafts, and read and approved final manuscript.  
15  
16  
17  
18

## 19 REFERENCES

- 20  
21  
22 1 Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in  
23 Australia in the new millennium: measuring health loss from diseases, injuries and risk factors.  
24 *Med J Aust* 2008;188:36-40.  
25  
26 2 American Diabetes Association. Diagnosis and classification of diabetes mellitus.  
27 *Diabetes Care* 2010;33 Suppl 1:S62-9.  
28  
29 3 Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a  
30 history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin*  
31 *Endocrinol Metab* 2008;93:4774-9.  
32  
33 4 Australian Institute of Health and Welfare. Diabetes prevalence in Australia: an  
34 assessment of national data sources. Canberra; 2009.  
35  
36 5 Mitanchez D, Burguet A, Simeoni U. Infants born to mothers with gestational diabetes  
37 mellitus: mild neonatal effects, a long-term threat to global health. *J Pediatr* 2014;164:445-50.  
38  
39 6 Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for  
40 mild gestational diabetes. *N Engl J Med* 2009;361:1339-48.  
41  
42 7 Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious  
43 adverse pregnancy outcome in 933 women with type 1 diabetes. *Diabetes Care* 2009;32:1046-8.  
44  
45 8 Garcia-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin  
46 requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of  
47 direction. *Diabetologia* 2010;53:446-51.  
48  
49 9 HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia  
50 and adverse pregnancy outcomes. *N Engl J Med* 2008;358:1991-2002.  
51  
52 10 Mitanchez D. Foetal and neonatal complications in gestational diabetes: perinatal  
53 mortality, congenital malformations, macrosomia, shoulder dystocia, birth injuries, neonatal  
54 complications. *Diabetes Metab* 2010;36:617-27.  
55  
56 11 Cardwell CR, Stene LC, Ludvigsson J, et al. Breast-feeding and childhood-onset type 1  
57 diabetes: A pooled analysis of individual participant data from 43 observational studies. *Diabetes*  
58 *Care* 2012;35:2215-25.  
59  
60 12 Patelarou E, Girvalaki C, Brokalaki H, Patelarou A, Androulaki Z, Vardavas C. Current  
evidence on the associations of breastfeeding, infant formula, and cow's milk introduction with  
type 1 diabetes mellitus: a systematic review. *Nutr Rev* 2012;70:509-19.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 13 Ip S, Chung M, Raman G, et al. Breastfeeding and Maternal and Infant Health Outcomes in Developed Countries. Rockville, MD: Agency for Healthcare Research and Quality; 2007 April 2007.
- 14 Webster J, Moore K, McMullan A. Breastfeeding outcomes for women with insulin dependent diabetes. *J Hum Lact* 1995;11:195-200.
- 15 Hummel S, Winkler C, Schoen S, et al. Breastfeeding habits in families with Type 1 diabetes. *Diabet Med* 2007;24:671-6.
- 16 Schoen S, Sichert-Hellert W, Hummel S, Ziegler AG, Kersting M. Breastfeeding duration in families with type 1 diabetes compared to non-affected families: results from BABYDIAB and DONALD studies in Germany. *Breastfeed Med* 2008;3:171-75.
- 17 Finkelstein SA, Keely E, Feig DS, Tu X, Yasseen AS, 3rd, Walker M. Breastfeeding in women with diabetes: lower rates despite greater rewards. A population-based study. *Diabet Med* 2013.
- 18 Stage E, Norgard H, Damm P, Mathiesen E. Long-term breast-feeding in women with type 1 diabetes. *Diabetes Care* 2006;29:771-4.
- 19 Kulski JK, Smith M, Hartmann PE. Perinatal concentrations of progesterone, lactose and alpha-lactalbumin in the mammary secretion of women. *J Endocrinol* 1977;74:509-10.
- 20 Murtaugh MA, Ferris AM, Capacchione CM, Reece EA. Energy intake and glycemia in lactating women with type 1 diabetes. *J Am Diet Assoc* 1998;98:642-8.
- 21 Arthur PG, Kent JC, Hartmann PE. Metabolites of lactose synthesis in milk from diabetic and nondiabetic women during lactogenesis II. *J Pediatr Gastroenterol Nutr* 1994;19:100-08.
- 22 Bitman J, Hamosh M, Hamosh P, et al. Milk composition and volume during the onset of lactation in a diabetic mother. *Am J Clin Nutr* 1989;50:1364-69.
- 23 Miyake A, Tahara M, Koike K, Tanizawa O. Decrease in neonatal suckled milk volume in diabetic women. *Eur J Obstet Gynecol Reprod Biol* 1989;33:49-53.
- 24 Neubauer SH, Ferris AM, Chase CG, et al. Delayed lactogenesis in women with insulin-dependent diabetes mellitus. *Am J Clin Nutr* 1993;58:54-60.
- 25 Nommsen-Rivers LA, Dolan LM, Huang B. Timing of stage II lactogenesis is predicted by antenatal metabolic health in a cohort of primiparas. *Breastfeed Med* 2012;7:43-9.
- 26 Hawkins JS, Casey BM. Labor and delivery management for women with diabetes. *Obstet Gynecol Clin N Am* 2007;34:323-34.
- 27 Beucher G, Viaris de Lesegno B, Dreyfus M. Maternal outcome of gestational diabetes mellitus. *Diabetes Metab* 2010;36:522-37.
- 28 Amir LH, Donath S. A systematic review of maternal obesity and breastfeeding intention, initiation and duration. *BMC Pregnancy Childbirth* 2007;7:9.
- 29 Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. *Diabetes Care* 2006;29:1105-07.
- 30 Remsberg KE, McKeown RE, McFarland KF, Irwin LS. Diabetes in pregnancy and cesarean delivery. *Diabetes Care* 1999;22:1561-7.
- 31 Simmons D, Conroy C, Thompson CF. In-hospital breast feeding rates among women with gestational diabetes and pregestational Type 2 diabetes in South Auckland. *Diabetic Med* 2005;22:177-81.
- 32 Renfrew M, Craig D, Dyson L, et al. Breastfeeding promotion for infants in neonatal units: a systematic review and economic analysis. *Health Technol Assess* 2009;13:1-146.

- 1  
2  
3 33 Cox SG. Expressing and storing colostrum antenatally for use in the newborn period.  
4 *Breastfeed Rev* 2006;14:11-6.  
5  
6 34 Rietveld C. Antenatal colostrum harvesting for pregnant women with diabetes mellitus  
7 (DM) (Poster). Midwifery Conference. New Zealand, 2011.  
8  
9 35 Chapman T, Pincombe J, Harris M, Fereday J. Antenatal breast expression: exploration  
10 and extent of teaching practices amongst International Board Certified Lactation Consultant  
11 midwives across Australia. *Women Birth* 2013;26:41-8.  
12  
13 36 Brisbane JM, Giglia RC. Experiences of expressing and storing colostrum antenatally: A  
14 qualitative study of mothers in regional Western Australia. *J Child Health Care* Published online  
15 first: 23 Oct 2013; doi 10.1177/1367493513503586.  
16  
17 37 Tozier PK. Colostrum versus formula supplementation for glucose stabilization in  
18 newborns of diabetic mothers. *JOGGN* 2013;42:619-26.  
19  
20 38 East CE, Dolan WJ, Forster DA. Antenatal breast milk expression by women with  
21 diabetes for improving infant outcomes. *Cochrane Database Syst Rev* 2014;7:CD010408.  
22  
23 39 Cairns and Hinterland Health Service District. Antenatal expression of colostrum  
24 procedure: Queensland Government; 2008.  
25  
26 40 Logan Hospital, Women's and Children's Health Service. Breastfeeding Information for  
27 Pregnant Women with Diabetes. 2009.  
28  
29 41 West D, Marasco L. Getting your milk supply off to a good start. The Breastfeeding  
30 Mother's Guide to Making More Milk. New York: McGraw-Hill, 2009;57-67.  
31  
32 42 Soltani H, Scott AM. Antenatal breast expression in women with diabetes: outcomes  
33 from a retrospective cohort study. *Int Breastfeed J* 2012;7:18.  
34  
35 43 Forster DA, McEgan K, Ford R, et al. Diabetes and antenatal milk expressing: a pilot  
36 project to inform the development of a randomised controlled trial. *Midwifery* 2011;27:209-14.  
37  
38 44 Forster DA, Amir LH, Moorhead A, et al. Is *not* testing a major change in clinical  
39 practice an ethical dilemma? (Letter). *Midwifery* 2011;27:e301-2.  
40  
41 45 Lawrence RA, Lawrence RM. Diabetes mellitus. Breastfeeding: A Guide For The  
42 Medical Profession. 5th ed. St Louis: Mosby, 1999;515-21.  
43  
44 46 Ho HT, Yeung WK, Young BW. Evaluation of "point of care" devices in the  
45 measurement of low blood glucose in neonatal practice. *Arch Dis Child Fetal Neonatal Ed*  
46 2004;89:F356-9.  
47  
48 47 Bonacruz GL, Arnold JD, Leslie GI, Wyndham L, Koumantakis G. Survey of the  
49 definition and screening of neonatal hypoglycaemia in Australia. *J Paediatr Child Health*  
50 1996;32:299-301.  
51  
52 48 Australian Government Department of Health and Ageing. National Hospital Cost Data  
53 Collection, Cost Weights for AR-DRG version 6.0x, Round 14 (2009-10). Canberra; 2012.  
54  
55 49 Australian Government Department of Health and Ageing. Medical Benefits Schedule  
56 Book. Canberra; 2011.  
57  
58 50 Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for  
59 reporting parallel group randomised trials. *PLoS Med* 2010;7:e1000251.  
60  
51 51 Ezzy D. Coding data and interpreting text: methods of analysis. *Qualitative Analysis:  
52 Practice and Innovation*. Sydney: Allen & Unwin, 2002;81-110.  
53  
54 52 Cox S. An ethical dilemma: should recommending antenatal expressing and storing of  
55 colostrum continue? *Breastfeed Rev* 2010;18:5-7.  
56  
57 53 Chapman T, Pincombe J, Harris M. Antenatal breast expression: a critical review of the  
58 literature. *Midwifery* 2013;29:203-10.

## Figure

**Figure 1. Schedule of enrolment, intervention, and assessments for the DAME (Diabetes and Antenatal Expressing) trial**

### **Supplementary files**

**Supplementary file 1: Instructions for hand expressing and storage of colostrum (early breast milk) for the Diabetes & Antenatal Milk Expressing (DAME) trial**

**Supplementary file 2: Safety committee terms of reference**



## Instructions for hand expressing and storage of colostrum (early breast milk) for the Diabetes & Antenatal Milk Expressing (DAME) trial

As part of the DAME trial you have been allocated to begin expressing colostrum (early breast milk) from 36 weeks of pregnancy. This information sheet will answer some questions you may have about expressing and storing your breast milk at home.

### How often do I express and for how long?

- Express twice a day, e.g. once in the morning, once in the evening.
- Express for about 10 minutes in total per session, for about 5 minutes each breast.
- If there is little or no colostrum expressed – don't worry, it is normal for women to produce varying amounts of colostrum.
- After you have expressed each time, and once you have stored your expressed colostrum, record the date and time you expressed in the expressing diary we have given you. Include the amount of colostrum you obtained as well as how long you expressed and any other comments you want to add.

### How do I collect and store the colostrum?

- You have been given syringes to collect the colostrum.
- You may find it easier to collect the colostrum onto a clean teaspoon. Wash the teaspoon first with hot soapy water, then draw the colostrum up from the teaspoon into the syringe for storage (or pour into one of the small pots if you have a larger amount).
- You can use one syringe to collect all your colostrum for 24 hours, but always use a new syringe or pot each day. If you need to use more than one syringe or pot per day then ensure **all** are labelled.
- Place the stopper on the end of the syringe before storing it in the refrigerator or freezing.
- Label the syringes with the labels we have given you. The labels include your name, your hospital number and your date of birth. You will need to **add** the date and time of the first colostrum expressed in to any syringe (so you will have a new label with your details on each 24 hours).
- Place each syringe/pot into the freezer within 24 hours of first using it to store the colostrum. In other words, you can store your expressed milk in the refrigerator for up to 24 hours, and keep adding to it during this time, but then it needs to be frozen.

### How do I hand express?

Before you start, always wash your hands with warm water and soap. You may find expressing after a warm bath or shower helps with the flow of colostrum. Sometimes gentle massage of your breasts before expressing may help. The DAME research midwife will have shown you how to express, but the instructions are here as well.

- Place the pads of your thumb and forefinger opposite each other on the outer edge of your areola and then gently press them back in to your breast tissue and squeeze together rhythmically. This should not be painful.
- Move your fingers around the areola to express all the milk ducts (like moving around the face of a clock).
- Express until the flow stops (up to 5 minutes, but not more) then change to the other breast.
- If your hand tires, swap to the other hand or have a rest.
- Remember – do not worry if there is little or no colostrum.
- Contact the DAME midwife if you need any further expressing advice.

### What should I look out for?

Hand expressing while you are pregnant may cause an increase of the hormone oxytocin in your blood. This may cause some tightenings (mild contractions) in your uterus. In accordance with your usual care as a pregnant woman with diabetes, you may be having monitoring of your baby's heart rate (CTG monitoring). After the first expressing session in hospital you can continue twice daily expressing at home. If you have any monitoring of your baby's heart rate we ask you to do one of your daily expressings during the monitoring so we can make sure everything is going well and write that in the expressing record book we have given you .

It is unlikely that expressing will cause any problems, however before you express at home it is important that:

- You are not experiencing any abdominal or labour pains; and
- Your baby is moving normally.

If you are not sure that your baby is moving normally, you should not express and you should contact the Emergency Department (which is the same as we tell all pregnant women).

### If you notice any of the following things during or after expressing:

- A prolonged tightening (lasting more than 1 minute);
- Very frequent tightenings (more than 5 in 10 minutes);
- Any bleeding; or
- A reduction in the baby's movements;

You should stop expressing and contact Emergency Department for advice.

### Do I monitor my blood sugar whilst expressing?

- Today we have checked your blood sugar level following the first time you expressed
- For the next two times you express (at home) please check your blood sugar level and record it in your expressing diary as well as where you usually record it (e.g. your blood glucose record) Do this after you have expressed and at the same time as you would normally check do a blood sugar check, for example, start expressing about half an hour before your blood sugar level is due. This will reduce the need for extra blood testing.
- Treat any abnormal blood sugar level reading as you would do normally. That is, contact the Diabetes Educator or Emergency Department if you are concerned.

### What happens when I come in to hospital to have my baby?

- Bring your frozen colostrum in with you when you come in to hospital to have your baby.
- Please bring it in the esky we gave you, packed with a frozen cold pack (there was one with the esky we gave you).
- Give the esky to the midwife when you arrive at the hospital and tell her it contains your frozen colostrum.
- It will be stored in the freezer in Ward 4 East (in the milk room).

### Contact numbers:

**Emergency Department The Womens' Hospital**  
**DAME Research Midwife/Coordinator**  
**Diabetes Educator**

**03 8345 3636**  
**03 8345 2932**  
**03 8345 2153**



# Diabetes and Antenatal Milk Expressing (DAME) Trial

ACTRN12611000217909

## SAFETY COMMITTEE TERMS OF REFERENCE

The purpose of this document is to describe the roles and responsibilities of the Safety Committee for the DAME trial including the timing of meetings, methods of providing information to and from the Safety Committee, frequency and format of meetings and relationships with other committees.

### Aims

To safeguard the interests of trial participants by assessing the safety of participation, and to assist and advise the principal investigators so as to protect the credibility of the trial.

### Relationships

The Safety Committee reports to the DAME principal investigators. A Data Monitoring Committee will be reporting separately on recruitment progress and accruing data from the trial.

### Specific roles of the Safety Committee

- To review reports of serious adverse outcomes in both trial arms to identify possible contributing factors related to participation in the trial and any association with either trial arm
- To advise the principal investigators if the Safety Committee has concerns about the safety of participants that might require the trial's early termination

The adverse events that the Safety Committee will be required to report on are:

- Perinatal/infant outcomes
  - Fetal compromise associated with expressing as evidenced by:
    - a) any abnormality on any a CTG during/following expressing (within four hours); or
    - b) decreased fetal movements during/following expressing (within four hours) necessitating presentation to hospital for fetal monitoring and/or cessation of the intervention;
  - Moderate to severe encephalopathy with or without seizures;
  - Admission to NICU/NISC for respiratory support (defined as respiratory support greater than four hours);
  - Perinatal death.
- Maternal
  - Maternal hypoglycaemia within half an hour of expressing (defined by a blood glucose level less than 4 mmol/l or symptoms requiring treatment<sup>1</sup>)
  - Abdominal pain after antenatal expressing –within 4 hours
  - Vaginal bleeding after antenatal expressing –within 4 hours

---

<sup>1</sup> Women will have received a list of symptoms of hypoglycaemia as part of their pregnancy care, and those defined by Diabetes Australia, Victoria are weakness, trembling or shaking, sweating, light headedness, headache, lack of concentration/behaviour change, dizziness, tearful/crying, Irritability, numbness around the lips and fingers, hunger.



TIMEPOINT	Enrolment	Allocation	Post-allocation				Close-out
	34-36 weeks of pregnancy	36 weeks of pregnancy	Allocation	Admission for birth	1-2 weeks postpartum	12 weeks postpartum	$t_x$
<b>ENROLMENT:</b>							
Eligibility screen	X						
Informed consent	X						
CTG	X						
Allocation		X					
<b>INTERVENTIONS:</b>							
Hand expressing twice/day for 10 mins			←→				
<b>ASSESSMENTS:</b>							
Maternal characteristics (in person)	X						
Maternal expressing diary (intervention group)			←→				
Obstetric data (abstracted from medical record)							X
Neonatal data (abstracted from medical record)							X
Infant feeding and onset of lactation data (telephone)					X		
Infant feeding data (telephone)						X	
Economic data							X

CTG: cardiotocograph

Figure 1. Schedule of enrolment, intervention, and assessments for the DAME (Diabetes and Antenatal Expressing) trial  
90x111mm (300 x 300 DPI)